European Neuropsychopharmacology

Are there differences between the role of monoamine systems in the pathophysiology of depression and the mechanisms of antidepressant drug action: Evidence from neurotransmitter depletion studies
pp. 77-77(1)
Author: Delgado P.L.

Progress and limitations in the evaluation of drug treatment for negative symptoms
pp. 77-78(2)
Author: Moller H.-J.

Molecular studies of enzymes involved in steroid biosynthesis in the central nervous system
pp. 79-79(1)
Authors: Compagnone N.A.; Mellon S.H.

Neurosteroids and the peripheral benzodiazepine receptor
pp. 79-80(2)
Authors: Papadopoulos V.; Brown R.C.; Cascio C.

Progesterone synthesized in peripheral nerves promotes myelin repair and axonal regeneration
pp. 80-80(1)
Authors: Schumacher M.; Guennoun R.; Robert F.; Desarnaud F.; Jung-Testas I.; Koenig H.; Ferzaz B.; Shazand K.; Baulieu E.E.

Memory and cognition: A role for neurosteroids
pp. 80-81(2)
Authors: Le Moal M.; Vallee M.; Darnaudery M.; Pallares M.; Simon H.; Mayo W.

The effects of clomethiazole in animal models of stroke
pp. 81-81(1)
Authors: Green A.R.; Cross A.J.

Advantages and disadvantages of lithium augmentation
pp. 82-82(1)
Author: Baumann P.

Fast onset: An open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy
pp. 82-83(2)
Authors: Bakish D.; Hooper C.L.; Thornton M.; Wiens A.; Miller C.; Thibaudeau C.

Total sleep deprivation and consecutive sleep-phase-advance as a therapeutic strategy in refractory depression
pp. 83-83(1)
Authors: Berger M.; Konig A.; Hohagen F.; Kiemen A.; Voderholzer U.; Riemann D.

Prioritizing augmentation strategies in resistant depression
pp. 83-84(2)
Author: Nolen W.A.

Epidemiology of social phobia
pp. 84-85(2)
Author: Angst J.

Implications of early onset social phobia on outcome
pp. 85-85(1)
Author: Leerubier Y.

Biological basis for social phobia
pp. 85-86(2)
Authors: Lydiard R.B.; Johnson M.R.

The pharmacological treatment of social phobia
pp. 86-86(1)
Authors: Baldwin D.S.; Birtwistle J.

Overview of CRF in psychiatric diseases
pp. 86-86(1)
Author: Nemeroff C.B.

Corticotropin releasing factor receptors and its binding protein: molecular, pharmacological and localization studies
pp. 87-87(1)
Authors: De Souza E.B.; Liaw C.W.; Grigoriadis D.E.

CRF-receptor ligands: Insights into the mode of receptor-peptide interaction
pp. 88-88(1)
Authors: Beyermann M.; Sasse A.E.; Fechner K.; Furkert J.; Heinrich N.; Berger H.; Kaupp U.B.; Bienert M.

Corticotropin-releasing factor and anxiety: Animal studies
pp. 88-89(2)
Authors: Moreau J.-L.; Kilpatrick G.; Jenck F.; Hoffmann F.

Future perspectives in CRH research
pp. 89-89(1)
Author: Holsboer F.

Does early treatment have an effect on outcome?
pp. 89-90(2)
Authors: Johnstone E.C.; Owens D.G.C.

Choice of drug to improve cognitive function
pp. 90-90(1)
Author: van Kammen D.P.

Guidelines for investigating drugs in schizophrenia
pp. 90-91(2)
Author: King D.J.

Impact of chronobiology for treatment of affective disorders
pp. 91-91(1)
Author: Linkowski

Therapeutic sleep deprivation: Lessons for psychopharmacology?
pp. 91-92(2)
Authors: Neumeister A.; Praschak-Rieder N.; Heszelmann B.; Kasper S.

Serotonergic side effects
pp. 92-92(1)
Author: Thompson C.

Electroconvulsive therapy: Acute treatment and long term perspective
pp. 92-93(2)
Authors: Shapira B.; Lerer B.

The effects of transcranial magnetic stimulation on -adrenergic receptors and brain monoamines
pp. 93-94(2)
Authors: Belmaker R.H.; Grisaru N.; Klein E.; Ben-Shachar D.

The use of gene targeting to study the biological roles of metabotropic glutamate receptors
pp. 94-94(1)
Author: Hampson D.R.

The metabotropic glutamate receptors: Structural domains and coupling to G proteins
pp. 94-94(1)
Authors: Pin J.-P.; Gomeza J.; Mary S.; Parmentier M.-L.; Joly C.; Restituito S.; De Colle C.; Bockaert J.

Group 1 and group 2 metabotropic glutamate receptor agents: Pharmacological studies in vitro and in vivo
pp. 95-95(1)
Authors: Moroni F.; Cozzi A.; Pellegrini-Giampietro D.; Leonardi P.; Attucci S.; Peruginelli F.; Mannaioni G.; Pellicciari R.

Pharmacological probes for metabotropic glutamate receptors: Structure-activity relationships
pp. 95-96(2)
Author: Roberts P.J.

Mechanisms underlying the neuroprotective activity of group-II metabotropic glutamate receptors IIN culture
pp. 96-96(1)
Authors: Bruno V.; Copani A.; Battaglia G.; N'Tonga R.; Caciagli F.; Knopfel T.; Nicoletti F.

Animal models of relapse
pp. 96-97(2)
Authors: Spanagel R.; Holter S.M.

Endorphins and relapse; Basic studies
pp. 97-98(2)
Authors: van Ree J.M.; Gerrits M.A.F.M.

Psychological strategies for relapse prevention in alcoholism
pp. 98-98(1)
Author: van den Brink W.

Pharmacotherapy of relapse prevention in alcoholism
pp. 98-99(2)
Author: Sass H.

Relapse prevention with opioid agonists and antagonists in heroin addiction
pp. 99-99(1)
Authors: Fischer G.; Eder H.; Jagsch R.; Diamant K.; Gombas W.; Kasper S.

Are rapid onset and superior outcome related?
pp. 99-100(2)
Author: Blier P.

Potential rapid onset: Mechanisms of action
pp. 100-101(2)
Author: Artigas F.

Can we identify subgroups for targeted adjunctive treatment?
pp. 101-101(1)
Author: Isaac M.T.

Predictors of response
pp. 101-102(2)
Author: Marazziti D.

Differences among anti-obsessive medications
pp. 102-102(1)
Authors: Bisserbe J.-C.; Flament M.

How long is long enough in treatment of obsessive compulsive disorders?
pp. 102-102(1)
Author: Zapotoczky H.G.

Obsessive compulsive disorders: Treatment algorithms and economic costs
pp. 102-103(2)
Authors: Hollander E.; Kornwasser J.W.; Wong C.

Interactions between CCK, dopamine, glutamate and aspartate in the rat striatum
pp. 103-103(1)
Authors: Hokfelt T.; Blacker D.; Broberger C.; Herrera-Marschitz M.; Ogren S.-O.

Pharmacology of the human CRF₁, CRF₂ and CRF₂ receptors and CRF binding protein
pp. 103-104(2)
Authors: Ardati A.; Gottowik J.; Valdenaire O.; Giller T.; Breu V.; Goetschy V.; Henriot S.; Deuschle U.; Moreau J.-L.; Kilpatrick G.J.

Galanin receptors and their functional characterization
pp. 104-105(2)
Authors: Ogren S.O.; Kehr J.; Schott P.A.; Snitt K.

The impact of the search for novel neuropeptides on psychopharmacology
pp. 105-105(1)
Authors: Civelli O.; Nothacker H.P.; Reinscheid R.

Predictors of response to neuroleptic treatment in schizophrenia
pp. 105-106(2)
Author: Kahn R.S.

The search for molecular biological determinants for psycho-pharmacological treatment in schizophrenia
pp. 106-107(2)
Authors: Aschauer H.N.; Scharfetter J.; Fuchs K.; Hornik K.; Kapitany T.; Lenzinger E.; Meszaros K.; Chaudhry H.R.; Sieghart W.; Kasper S.

Treatment resistence: Are there specific strategies?
pp. 107-107(1)
Author: Gerlach J.

Stress, depression and hormones
pp. 108-108(1)
Author: Young E.A.

Gonadal steroids, brain, and behavior
pp. 108-108(1)
Authors: Rubinow D.R.; Schmidt P.J.

Serotonin reuptake inhibitors in the treatment of premenstrual dysphoria
pp. 108-108(1)
Author: Steiner M.

Identification and treatment of postpartum depression
pp. 108-109(2)
Authors: Stowe Z.N.; Llewellyn A.M.; Strader J.R.; Landry J.C.; Owens M.J.; Ritchie J.; Kilts C.D.; Nemeroff C.B.

The HPA axis and the pathophysiology of depression: The role of early adverse experience
pp. 109-109(1)
Authors: Nemeroff C.B.; Owens M.J.; Plotsky P.

Regulation of transcription factors by signal transduction pathways
pp. 109-109(1)
Author: Yaniv M.

Modulation of signal-regulated transcription factors by antipsychotics
pp. 109-110(2)
Authors: Rogue P.; Vincendon G.

Antipsychotic drugs and neurotransmitter receptor regulation
pp. 110-111(2)
Author: Reynolds G.P.

Regulation of glutamate receptor gene expression in response to antipsychotic drug treatment
pp. 111-111(1)
Authors: Riva M.A.; Tascedda F.; Lovati E.; Massironi A.; Racagni G.

Molecular genetics of bipolar disorders: Implication for psychotropic drugs
pp. 112-113(2)
Authors: Lipp O.; Mahieu B.; Souery D.; Serretti A.; Cavallini C.; Verga M.; Van Broeckhoven C.; Macciardi F.; Mendlewicz J.

Schizophrenia - Pharmacoeconomic consequences of negative symptoms
pp. 113-113(1)
Author: Souetre E.

Change in negative symptoms during treatment with psychopharmacologic agents?
pp. 113-114(2)
Authors: Olie J.P.; Galinowski A.

Efficacy of new antipsychotics in negative symptoms
pp. 114-114(1)
Authors: Kasper S.; Tauscher J.; Pezawas L.; Barnas C.; Kufferle B.; Aschauer H.

Evidence of efficacy of neuroleptics in effective versus negative symptoms
pp. 114-115(2)
Author: Naber D.

Non neuroleptic treatments for negative symptoms
pp. 115-115(1)
Author: Altamura A.C.

Biological basis for treatment of anorexia nervosa
pp. 115-116(2)
Author: Halmi K.A.

Is there a specific psychopharmacology for eating disorders?
pp. 116-117(2)
Author: de Zwaan M.

Pharmacological maintenance strategies for bulimia nervosa
pp. 117-117(1)
Author: Fichter M.M.

Comparison of treatment outcome in children and in adults with OCD
pp. 117-118(2)
Author: Buitelaar J.K.

Challenge studies in obsessive-compulsive disorder; A key to the pathogenesis?
pp. 118-119(2)
Authors: Den Boer J.A.; Westenberg H.G.M.

Function and regulation of the expression of the D₃ receptor: Therapeutic implications
pp. 119-120(2)
Authors: Sokoloff P.; Bordet R.; Griffon N.; Pilon C.; Sautel F.; Diaz J.; Ridray S.; Schwartz J.-C.

Evaluation of D3 receptor antagonists
pp. 120-120(1)
Authors: Gross G.; Bialojan S.; Drescher K.; Freeman A.S.; Garcia-Ladona F.J.; Hoger T.; Lansky A.; Needham P.; Teschendorf H.-J.; Treiber H.-J.; Traut M.; Sokoloff P.; Starck D.; Unger L.; Wicke K.

Dopamine D4 receptor antagonists, schizophrenia and beyond?
pp. 120-121(2)
Author: Patel S.

Pharmacological characterization of dopamine D3 and D4 receptor ligands
pp. 121-122(2)
Author: Svensson K.A.

Clinical importance of D3/D4 receptor antagonists
pp. 122-122(1)
Authors: Ackenheil M.; Messer T.; Muller N.

How should we treat mania?
pp. 122-123(2)
Author: Goodwin G.

Long-term prophylactic treatment priorities in bipolar disorder
pp. 123-124(2)
Author: Bowden C.L.

Rapidly cycling bipolar disorder: Overview of the concept and empirical findings
pp. 124-124(1)
Author: Maj. M.

Implications of comorbidity for treatment in bipolar disorder
pp. 124-124(1)
Author: Bourgeois M.L.

SSRIs and other new treatments in panic disorder
pp. 124-125(2)
Author: Rosenberg R.

5HT_1B and 5HT_1D receptor subtypes, localisation studies, towards the untangling of their roles
pp. 125-126(2)
Authors: Leysen J.E.; Bonaventure P.; Luyten W.H.M.L.; Schotte A.; Voorn P.

Long-term treatment of Panic Disorder-Agoraphobia
pp. 125-125(1)
Authors: Cassano G.B.; Toni C.; Perugi G.

Neuroendocrine assessment of 5-HT1a receptors
pp. 126-127(2)
Authors: Ansseau M.; Pitchot W.; Hansenne M.

Modulation of serotonin 5HT_1B receptor by an endogenous peptide
pp. 127-128(2)
Authors: Fillion G.; Massot O.; Rousselle J.C.; Grimaldi B.; Bonnin A.; Fillion M.P.; Cloez-Tayarani I.; Seguin L.; Seznec J.C.; Prudhomme N.; Plantefol M.

The 5-HT_2C receptor-potential therapeutic opportunities
pp. 128-128(1)
Author: Blackburn T.P.

Relationship between D₂ receptor occupancy and extrapyramidal side effects
pp. 128-129(2)
Authors: Kufferle B.; Tauscher J.; Barnas C.; Asenbaum S.; Brucke T.; Kasper S.

A PET-study of extrastriatal D2-dopamine receptors
pp. 129-130(2)
Author: Farde L.

EEG/ERP-mapping as a tool in psychopharmacology
pp. 130-130(1)
Authors: Saletu B.; Anderer P.; Pascual-Marqui R.; Semlitsch H.V.

Structural brain imaging: Relationship to treatment response and clinical outcome of schizophrenia
pp. 130-131(2)
Author: Vita A.

Psychopharmacology of impulsivity and aggression in childhood and adolescence
pp. 131-132(2)
Author: Taylor E.

Clozapine metabolism in early onset schizophrenia
pp. 132-132(1)
Authors: Schulz E.; Fleischhaker C.; Remschmidt H.

Exelon^TM in Alzheimer's disease
pp. 132-132(1)
Authors: Gharabawi G.; Anand R.; Hartmann R.; Messina J.

Muscarinic agonists in the treatment of Alzheimer's disease
pp. 132-133(2)
Author: Kumar R.

The role of antidepressants in the treatment of dementia
pp. 133-134(2)
Authors: Muller-Spahn F.; Hock C.

SSRI use in a French general practitioner (GP) setting, for patients with a diagnosis of depression
pp. 135-135(1)
Authors: Allicar M.P.; Breton M.; France L.

The use and tolerability of venlafaxine in old depressed patients
pp. 135-135(1)
Authors: Amore M.; Ricci M.; Perez J.; Ferrari G.

Clinical experience with citalopran in the treatment of depression in the elderly
pp. 135-135(1)
Authors: Aragues E.; Malo E.M.; Pacheco P.; Aragues L.

Predictors of outcome in depression in treatment with selective serotonin reuptake inhibitors
pp. 136-136(1)
Authors: Arias F.; Padin J.J.; Cabo J.; Alvarez C.; Mateos M.B.; Gallego M.T.

Trazodone and priapism
pp. 136-136(1)
Authors: Askin R.; Kaya N.; Cilli A.S.

Dimensional study of separation anxiety in adults
pp. 136-136(1)
Authors: Atger F.; Aloupis P.; Kentin S.; Fouillet M.; Dao-Castellana M.-H.; Verot D.; Consoli S.; Braconnier A.

Analysis of the utilization of anxiolytics and sedative-hypnotics prior to and post initiation of an SSRI for the treatment of depression
pp. 136-137(2)
Authors: Baldridge R.M.; Hylan T.R.; Meneades L.; Crown W.H.

The role of paroxetine in the treatment of anxiety disorders
pp. 137-137(1)
Authors: Baldwin D.S.; Birtwistle J.

Paroxetine plasmatic levels and clinical response in major depression
pp. 137-137(1)
Authors: Baron F.J.; Perez V.; Ferrer I.; Puigdemont D.; Queralto J.; Figueras M.; Alvarez E.

MAO-A and MAO-B differ in their stereoselective biotransformation of citalopram in human liver
pp. 137-138(2)
Authors: Rochat B.; Kosel M.; Baumann P.; Boss G.; Testa B.; Gillet M.

Antidepressant-associated hypomania in 203 depressed outpatients in private practice
pp. 138-138(1)
Author: Benazzi F.

A simple method for routine TDM of the SSRI sertraline and desmethylsertraline in serum by HPLC
pp. 138-138(1)
Authors: Bjork H.; Bengtsson F.

A HPLC-method for routine TDM of the novel antidepressant venlafaxine and its main metabolites in serum
pp. 138-138(1)
Authors: Bjork H.; Bengtsson F.

Mirtazapine oral single dose kinetics in patients with different degrees of renal failure
pp. 138-139(2)
Authors: Bengtsson F.; Hoglund P.; Timmer C.; Hegbrant J.

Animal models suggest that mirtazapine broadens the therapeutic window of haloperidol
pp. 139-139(1)
Authors: Berendsen H.H.G.; Broekkamp C.L.E.; Pinder R.M.

Effects of a single venlafaxine challenge on the neocortical monoamine output in experimental chronic hepatic encephalopathy
pp. 139-139(1)
Authors: Bergqvist P.B.F.; Wikell C.; Hjorth S.; Apelqvist G.; Bengtsson F.

Early predictors of two months' response with mianserin and selective serotonin reuptake inhibitors
pp. 140-140(1)
Authors: Berlin I.; Lavergne F.

Safety of simultaneous treatment with electroconvulsive therapy and venlafaxine
pp. 140-140(1)
Authors: Arrufat F.J.; Bernardo M.; Navarro V.; Duran A.; Salva J.; Buisan E.

Thyroidal hormone profile in bipolar patients who were in short and long-term lithium treatment
pp. 140-141(2)
Authors: Sofuoglu S.; Tutus A.; Gonul A.S.; Basturk M.; Kose K.; Esel E.

Follow-up of bipolar patients who responded to lithium-carbamazepine combination
pp. 141-141(1)
Authors: Bocchetta A.; Ardau R.; Chillotti C.; Quesada G.; Del Zompo M.

Fluoxetine augmentation in citalopram non-responders: Pharmacokinetic and clinical consequences
pp. 141-141(1)
Authors: Bondolfi G.; Schekter C.L.; Kosel M.; Baumann P.

An investigation into the potential noradrenergic activity of the selective serotonin reuptake inhibitor (SSRI), paroxetine
pp. 141-141(1)
Authors: Bourin M.; Redrobe J.P.; Colombel M.C.

Dopamine D₂, D₃ and D₄ receptors and depression: Actions of selective ligands in the forced swim model of potential antidepressant properties in rats
pp. 142-142(1)
Authors: Brocco M.; Veiga S.; Audinot V.; Newman-Tancredi A.; Millan M.J.

Withdrawal symptoms after discontinuation of a citalopram treatment? A prospective study
pp. 142-142(1)
Authors: Bryois C.; Rubin C.; Voirol P.; Kosel M.; Baumann P.

Clinical features and response to selective serotonin reuptake inhibitors in patients with atypical depression
pp. 142-143(2)
Authors: Cecconi D.; Lattanzi L.; Mastrocinque C.; Patronelli A.; Vignoli S.; Bemi E.; Perugi G.

An open study with sertraline in outpatients with dysthymia
pp. 143-143(1)
Authors: Chinchilla A.; Vega M.; Cebollada A.

A study on the dosage and steady state plasma levels of imipramine in Chinese - Preliminary findings
pp. 143-143(1)
Authors: Chiu H.F.K.; Wing Y.K.; Chan K.

Amisulpride-induced behavioural sensitization: An antidepressant effect?
pp. 143-144(2)
Authors: Collu M.; Devoto P.; Porceddu M.; Del Zompo M.

Different mechanisms underlie fluoxetine- and imipramine-induced behavioural sensitization of dopamine receptors
pp. 144-144(1)
Authors: Collu M.; Fadda P.; Porceddu M.; Serra G.

Citalopram use and treatment outcome in an unselected Italian sample of major depressives
pp. 144-145(2)
Authors: Conte G.; Cauli G.; Sanna C.; Scarone S.

The role of clonidine in the treatment of manic episodes
pp. 145-145(1)
Authors: Conte G.; Calzeroni A.; Ferrari R.

Premenstrual dysphoric disorder: Long-term treatment and discontinuation of fluoxetine 20 MG
pp. 145-145(1)
Author: de la Gandara J.J.

In vivo study in humans on disposition of the enantiomers and metabolites of mirtazapine
pp. 145-145(1)
Authors: Delbressine L.; Dahl M.-L.; van den Wildenberg H.M.; Kleijn H.J.; Bertilsson L.

Pulse-dosing and conventional application of doxepine: Effects upon psychopathology and hypothalamus-pituitary-adrenal (HPA) system
pp. 146-146(1)
Authors: Deuschle M.; Schmider J.; Weber B.; Standhardt H.; Korner A.; Lammers C.-H.; Schweiger U.; Hartmann A.; Heuser I.

Efficacy of the association selective serotonin reuptake inhibitors + benzamides in the treatment of dysthymia
pp. 146-146(1)
Authors: Di Sciascio G.; Clemente P.; Calo P.

The use of drugs in depression the last decade
pp. 146-146(1)
Authors: Dorado R.; Masegoza M.; Casas N.; Conde M.; Martinez M.; Santisteban E.

The changes of the rat brain D₂ and D₃ dopamine receptors, following repeated treatment with antidepressants - An autoradiographic study
pp. 146-147(2)
Authors: Rogoz R.; Dziedzicka-Wasylewska M.; Maj J.

Dopamine and depression - Antidepressant therapies change dopaminergic neurotransmission - An IBZM SPECT study
pp. 147-147(1)
Author: Ebert D.

A double-blind study comparing sertraline and citalopram in patients with major depression treated in general practice
pp. 147-147(1)
Authors: Ekselius L.; von Knorring L.; Eberhard G.

Effect of pindolol in hastening response to serotoninergic antidepressants: An open study in severely depressed female in-patients
pp. 147-147(1)
Authors: Erfurth A.; Kammerer C.; Ackenheil M.; Moller H.-J.

Fluoxetine and dothiepin in depressed patients: A comparison of efficacy and effects on cognition and subjective sleep
pp. 148-148(1)
Authors: Fairweather D.B.; Stanley N.; Hindmarch I.

Dual (NA + 5-HT) versus single (5-HT) acting antidepressants, clinical overview
pp. 148-148(1)
Author: Falkai P.

Changes in GAP-43 protein, PKC isoenzymes, CRF and bombesin-like peptide levels in post-mortem brain of antidepressant-free depressed suicide victims
pp. 148-149(2)
Authors: Faludi G.; Palkovits M.; Hrdina P.D.; Li Q.; Kent P.; Merali Z.

Mechanisms of action of antidepressants
pp. 149-149(1)
Author: Frazer A.

Effects of fluoxetine on dopaminergic responses at the medial prefrontal cortex (mPFC)
pp. 149-149(1)
Authors: Gobbi G.; Janiri L.

Yohimbine is a potent, partial agonist at rat and cloned, human serotonin_1A receptors: A comparison to buspirone and its metabolite, 1-pyrimidinylpiperazine
pp. 149-150(2)
Authors: Gobert A.; Newman-Tancredi A.; Rivet J.M.; Audinot V.; Millan M.J.

Effects of first-trimester fluoxetine exposure on the newborn
pp. 150-150(1)
Authors: Goldstein D.; Corbin L.; Sundell K.

Treatment resistant depression - A biochemical hypothesis
pp. 150-150(1)
Authors: Gupta R.K.; Burrows G.; Norman T.

Refractory depression (A new model for definition)
pp. 150-151(2)
Authors: Gupta R.K.; Burrows G.; Thase M.

A multicenter six-month open trial of venlafaxine in major depression
pp. 151-151(1)
Authors: Ayuso J.L.; Bayus C.; Carrasco J.L.; Giner J.; Moreno A.

Tryptophan depletion: A predictor for future depressive episodes?
pp. 151-151(1)
Authors: Habeler A.; Neumeister A.; Praschak-Rieder N.; Heszelmann B.; Willeit M.; Kasper S.

Mirtazapine in seasonal affective disorder (SAD) - A preliminary report
pp. 151-152(2)
Authors: Heszelmann B.; Habeler A.; Praschak-Rieder N.; Willeit M.; Kasper S.

Combined antidepressant therapy using mirtazapine and citalopram in therapy resistent depression
pp. 152-152(1)
Authors: Heszelmann B.; Kufferle B.; Praschak-Rieder N.; Barnas C.; Kasper S.

Efficacy and tolerability of venlafaxine alone and with lithium in patients with severe depression
pp. 152-152(1)
Authors: Hoencamp E.; Haffmans P.M.J.; Dijken W.A.; van Bargen B.

Depression associated with rheumatoid arthritis - Comparison of paroxetine and amitriptyline
pp. 152-153(2)
Author: Hunter B.

Antidepressant use in a general practitioner setting in the Netherlands
pp. 153-153(1)
Authors: Hylan T.R.; Pathiyal A.; Quik R.; Jones J.K.

Efficacy and tolerability of once-daily venlafaxine XR vs. fluoxetine and placebo in depressed outpatients with concomitant anxiety
pp. 153-153(1)
Authors: Silverstone P.; Iskandar H.; Hamel R.; Salinas E.

Analysis of antidepressant utilization in a new Belgian general practice database
pp. 153-154(2)
Authors: Jones J.K.; Devlies J.; Van Ganse E.; Pathiyal A.; Hylan T.R.

Amisulpride vs amitriptyline in the medium-term treatment of dysthymia: A safety study
pp. 154-154(1)
Authors: Jori M.C.; Natale C.; Cesana B.M.; Ravizza L.

Risk of adverse events and depressive symptom breakthrough following brief interruption of SSRI therapy
pp. 154-154(1)
Authors: Blomgren S.; Krebs W.; Wilson M.; Ascroft R.; Judge R.; Fava M.; Rosenbaum J.

Patient-rated improvements for sertraline non-responders treated with fluoxetine
pp. 154-155(2)
Authors: Judge R.; Wilson M.; Kim Y.; Birkett M.

A comparative study of sertraline vs. imipramine in post-psychotic depressive disorder of schizophrenia
pp. 155-155(1)
Authors: Kirli S.; Caliskan M.

Antidepressant theraphy response and age, number of episodes, duration of episodes, and family history of psychiatric disorder
pp. 155-155(1)
Authors: Kirli S.; Gulec C.; Kuey L.; Bekaroglu M.; Evlice Y.E.; Unal S.

Safety of sertraline in overdose in a 13 years old adolescent - Comparative toxicity study of antidepressants among children and adolescents
pp. 155-155(1)
Authors: Kochman F.; Ducrocq F.; Feinte P.; Parquet P.-J.

An open trial of serotonine specific reuptake inhibitors (SSRIs) in the treatment of psychotic depression among children and adolescents
pp. 155-156(2)
Authors: Kochman F.; Ducrocq F.; Parquet P.-J.

Use and understanding of antidepressant medications in primary care
pp. 156-156(1)
Authors: Kosky N.M.; Rasmussen J.G.C.

The use of mirtazapine in a group of 11 patients following poor compliance to SSRI treatment due to sexual dysfunction
pp. 156-156(1)
Authors: Koutouvidis N.; Pratikakis M.; Fotiadou A.; Istikoglou C.

Mirtazapine vs amitriptyline in relapse prevention: A placebo-controlled study
pp. 156-157(2)
Authors: Montgomery S.A.; Kremer C.M.E.

A randomized, double-blind comparison of mirtazapine and fluoxetine in patients with major depression
pp. 157-157(1)
Authors: Wheatley D.; Kremer C.M.E.

Tolerability of mirtazapine used in high or low initial dose
pp. 157-158(2)
Authors: Stahl S.M.; Kremer C.M.E.; Pinder R.M.

Lack of pharmacokinetic interactions between mirtazapine and lithium
pp. 158-158(1)
Authors: Sitsen A.J.M.; Kremer C.M.E.

The influence of trimipramine on hippocampal field potentials in the low Mg²⁺-model
pp. 158-158(1)
Authors: Langosch J.M.; Repp M.; Berger M.; Walden J.

Molecular-biology of seasonal affective disorder (SAD)
pp. 158-158(1)
Authors: Lenzinger E.; Neumeister A.; Praschak-Rieder N.; Willeit M.; Fuchs K.; Gerhard E.; Stompe T.; Sieghart W.; Hornik K.; Kasper S.; Aschauer H.N.

Citalopram in depressed cardiac patients
pp. 158-159(2)
Author: Lipavsky P.

Bipolar I disorder and affective temperament
pp. 159-159(1)
Authors: Madaro D.; Quilici C.; Socci C.; Tilli C.; Ruffolo G.; Simonini E.; Musetti L.

Effects of antidepressants on long term changes of TSH response to TRH in unipolar recurrent major depression
pp. 159-159(1)
Authors: Mahnert F.A.; Moestl B.; Schoenauer-Cejpek M.; Laure S.; Hoenigl D.; Schrittwieser U.; Hofmann P.; Zapotoczky H.G.

Prodromal and residual symptoms in recurrent depression: Preliminary data of a long-term study under prophylactic treatment condition
pp. 159-160(2)
Authors: Mahnert F.A.; Reicher H.; Zalaudek K.; Zapotoczky H.G.

The pharmacological profile of venlafaxine, a new antidepressant drug given acutely and chronically
pp. 160-160(1)
Authors: Maj J.; Dziedzicka-Wasylewska M.; Rogoz Z.; Skuza G.

Factors conditioning inter-rater concordance in clinical assessment of depressive state
pp. 160-160(1)
Author: Marconi P.L.

Agitated depression in elderly-safety treatment with moclobemide
pp. 160-161(2)
Authors: Marinkovic D.J.; Marinkovic O.

Lamotrigine: An alternative drug in the prophylaxis of bipolar disorders
pp. 161-161(1)
Authors: Mauri M.C.; Laini V.; Somaschini E.; Ami A.; Giannelli A.; Sostero M.

A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practise
pp. 161-161(1)
Authors: McPartlin G.M.; Reynolds A.; Anderson C.; Casoy J.; Boyd M.

Optimal length of continuation therapy: A prospective assessment during fluoxetine long-term treatment of major depressive disorder
pp. 161-162(2)
Authors: Michelson D.; Reimherr F.; Wilson M.; Judge R.; Beasley C.

Early and late adverse event profiles associated with fluoxetine treatment
pp. 162-162(1)
Authors: Michelson D.; Wilson M.; Judge R.; Beasley C.

Analgesic, sedative and antidepressant effects of noradrenergic antidepressants related to beta-adrenoceptors
pp. 162-162(1)
Authors: Mico J.A.; Rojas-Corrales O.; Serrano M.I.; Casas J.; Serrano J.S.; Gibert-Rahola J.

Immunotropic effect of nootrop in patients with major depression
pp. 162-162(1)
Author: Minenko S.

Pharmacotheraphy of depressive disorders in period of involution
pp. 162-163(2)
Author: Munjiza M.

Pharmacotherapy of pre-menstrual syndrome
pp. 163-163(1)
Authors: Munjiza M.; Ljubomirovic N.

SSRI antidepressant selection and anxiolytic and sedative-hypnotic use: A multivariate analysis
pp. 163-164(2)
Authors: Hylan T.R.; Neslusan C.A.; Baldridge R.M.; Meneades L.; Crown W.H.

Sensitivity of motor activity monitoring: A study in outpatients with treatment-resistant depression under phototherapy
pp. 164-164(1)
Authors: Dantchev N.; Raoux N.; Le Hir N.; Allilaire J.F.

The assessment of neuroendocrine function in major depression using the combined dexamethasone/CRH test
pp. 164-164(1)
Authors: Oshima A.; Higuchi T.; Tadokoro C.; Miyaoka H.; Kamijima K.

Trends in treating bipolar disorder during the last six years at a university clinic in Turkey
pp. 164-164(1)
Authors: Ozerdem A.; Tunca Z.; Kaya N.

Week two HAMD score predicts onset of action of TCA
pp. 164-165(2)
Authors: Pfeiffer H.; Scherer J.; Karg B.; Albus M.; Hecht S.; Scharff-Buessing S.; Kindermann K.

Clinical pharmacological profile of the RIMA RS-8359
pp. 165-165(1)
Authors: Plenker A.; Puchler K.; Iwata N.; Sasahara K.

Sad patients in stable summer remission: Persistent serotonergic dysfunction?
pp. 165-165(1)
Authors: Praschak-Rieder N.; Neumeister A.; Heelmann B.; Willeit M.; Vitouch O.; Kasper S.

The clinical relevance of the cytochrome P450 enzyme system to antidepressants
pp. 165-166(2)
Author: Preskorn S.

Early phase II results of the RIMA RS-8359
pp. 166-166(1)
Authors: Puchler K.; Plenker A.; Volz H.-P.

Changes in adrenergic cerebrovascular innervation following chronic neuropharmacological treatment of the rostral striatum
pp. 166-166(1)
Authors: Pugovkin A.P.; Yakimovski A.F.

Mirtazapine: An evaluation of the tolerability of initial doses of 15 and 30 mg in patients with major depressive disorder
pp. 166-167(2)
Authors: Radhakishun F.S.; van der Heijden B.C.J.M.; Roes K.C.B.; O'Hanlon J.F.

Prophylactic efficiency of lithium carbonicum, carbamazepine and valproin acid in affective disorders of adolescents
pp. 167-167(1)
Authors: Rajewski A.; Rajewska J.; Marcinkowski K.

Is manipulation of inositol/2nd messenger system, a therapeutic strategy for bipolar disorders? Effects of lithium, carbamazepine and lamotrigine
pp. 167-167(1)
Authors: Reibaud M.; Heuillet E.; Pasquet M.; Rouyer T.; Perrot F.; Imperato A.; Dubroeucq M.C.D.

The efficacy and tolerability of venlafaxine and paroxetine in outpatients with mild to moderate depression or dysthmia
pp. 167-168(2)
Authors: Ballus C.; Quiros G.; de Flores T.; de la Torre J.; Palao D.; Rojo L.; Gutierrez M.; Casais L.; Riesgo Y.

Combined therapy with tricyclic and monoamineoxidase inhibitor antidepressants in the treatment of resistant depression
pp. 168-168(1)
Author: Rosan T.A.

Does a lower initial starting dosage improve tolerability for once-daily venlafaxine XR?
pp. 168-168(1)
Authors: Venlafaxine XR 370 Study Group; Rudolph R.

Efficacy and tolerability of once-daily venlafaxine XR vs. fluoxetine and placebo in depressed outpatients
pp. 168-169(2)
Authors: Venlafaxine XR 211 Study Group; Rudolph R.

Influence of concomitant medications on fluoxetine in depression clinical trials
pp. 169-169(1)
Authors: Wernicke J.F.; Sayler M.E.; Koke S.C.; Tollefson G.D.

Adverse events and treatment discontinuations in fluoxetine clinical trials: An updated meta-analysis
pp. 169-169(1)
Authors: Plewes J.M.; Koke S.C.; Sayler M.E.

Fluoxetine in inpatients. A naturalistic study
pp. 169-169(1)
Authors: Serrano D.; Perez V.; Puigdemont D.; Perez J.; Alvarez E.

A double-blind multicentre trial of moclobemide vs imipramine in bipolar depression
pp. 169-170(2)
Author: Silverstone T.

Relationships between selected immunological parameters and cortisol in treatment resistant depression
pp. 170-170(1)
Authors: Sluzewska A.; Bosmans E.; Rybakowski J.

Double-blind, randomized study of venlafaxine, clomipramine, and trazodone in geriatric patients with major depression
pp. 170-170(1)
Authors: Smeraldi E.; Aguglia A.; Cattaneo M.; Cerati C.; Covelli C.; Del Zompo M.; Faravelli C.; Gerrari G.; Ghirlanda A.; Guazzelli G.; Mansi M.; Ravizza L.

Effects of lithium treatment on granulocytes and granulocyte-colony stimulating factor in patients with bipolar affective disorder
pp. 170-171(2)
Authors: Sofuoglu S.; Ozdemir M.A.; Basturk M.; Kilio H.; Kose K.; Gonul A.S.

The effects of fluoxetine and dothiepin on twenty four hour activity in depressed patients
pp. 171-171(1)
Authors: Stanley N.; Fairweather D.B.; Hindmarch I.

Interactions of steroid hormones and the serotonergic cascade in patients with dysthymia
pp. 171-171(1)
Authors: Dunn E.; Coote M.; Browne G.; Steiner M.

Carbohydrate-rich diet in experimental models of depression
pp. 172-172(1)
Authors: Djuric V.J.; Overstreet D.H.; Dragomir A.; Steiner M.

Biological correlates of irritability in women with premenstrual dysphoria
pp. 172-172(1)
Authors: Steiner M.; Coote M.; Wilkins A.; Dunn E.

Effects of phototherapy on sleep pattern in patients with seasonal affective disorder (SAD)
pp. 172-172(1)
Authors: Jernajczyk W.; Swiecicki L.

Adjunctive long term treatment of therapy resistant circular psychoses with flupentixoldecanoat
pp. 173-173(1)
Authors: Szabo E.; Erdelyi A.

Differential effects of chronic administration of fluvoxamine on serotonin in the rat hippocampus and raphe measured in vivo
pp. 173-173(1)
Authors: Tajima O.; Nara K.; Nakada S.; Murata S.

Pindolol addition shorten delay of action of paroxetine in major depression: A double blind controlled trial
pp. 173-173(1)
Authors: Thomas P.; Bordet R.; Alexandre J.Y.; Catteau J.; Cyran C.; Danel T.; Debieve J.; Dumon J.P.; Dumont P.; Dutoit D.; Duthoit D.; Geraud C.; Lalaux N.; Lanvin F.; Lebert F.; Louvrier J.; Maux J.P.; Plumecocq C.; Scottez B.; Servant D.; Trinh E.; Vaiva G.; Vignau J.; Thomas C.E.; Dupuis B.

Tolerability of mirtazapine in a naturalistic patient setting
pp. 173-174(2)
Authors: Timmerman L L.; Vester E E.

Combination of amitriptyline and fluvoxamine with lithium-carbonate in the treatment of major depressive disorder
pp. 174-174(1)
Authors: Timotijevic I.; Zdravkovic M.; Miljkovic B.; Pokrajac M.

Does amitriptyline influence plasma concentrations of fluvoxamine in patients on combined therapy?
pp. 174-174(1)
Authors: Miljkovic B.R.; Pokrajac M.; Timotijevic I.; Varagic V.

An open-label study of the clinical efficacy of tianeptine for depression: One center results of a multicenter study
pp. 174-175(2)
Authors: Tunca Z.; Alkin T.; Fidaner H.; Alptekin K.; Cimilli C.

Anxiolytic and sleep improving effects of mirtazapine in everyday clinical practice
pp. 175-175(1)
Authors: Vester E.; Helsdingen J.T.H.

Prediction of mania in euthymic bipolar patients using corticotropin-releasing factor challenge test
pp. 175-175(1)
Authors: Vieta E.; Gasto C.; Martinez-de-Osaba M.J.; Colom F.; Benabarre A.; Vallejo J.

Mobility patterns in bipolar affective disorder
pp. 175-175(1)
Authors: Webb M.G.T.; Abood Z.

Mirtazapine in old age depression
pp. 175-176(2)
Authors: Wittgens W.; Trenckmann U.

Carbamazepine versus lithium in the prophylaxis of bipolar affective disorders. A randomised, double-blind 1-year study in 168 patients
pp. 176-176(1)
Authors: The Hungarian Study Group for Prophylaxis of Bipolar Disorders; Wolf C.; Berky M.; Kovacs G.

Duration of hospitalisation and its modelings
pp. 176-176(1)
Authors: Zdanowics N.; Janne P.; Reynaert C.

Meta-analysis of randomized, double-blind, placebo-controlled studies of mirtazapine vs amitriptyline
pp. 176-177(2)
Authors: Stahl S.M.; Zivkov M.

Lamictal(R) Monotherapy in the treatment of bipolar disorder
pp. 177-177(1)
Authors: Calabrese J.; Bowden C.; McElroy S.; Cookson J.; Andersen J.; Watson C.; Ascher J.; Corn T.

Molecular genetic investigations of candidate loci in lithium responsive bipolar disorder - A study by IGSLI
pp. 177-177(1)
Authors: Alda M.; Turecki G.; Grof P.; Ahrens B.; Berghoffer A.; Cavazzoni P.; Duffy A.; Dvorakova M.; Grof E.; Holzinger A.; Joober R.; Libigerova E.; Licht R.W.; Martin R.B.; Muller-Oerlinghausen B.; Nilsson A.; Prochazka H.; Rasmussen N.A.; Rouleau G.; Schumann C.; Thau K.; Vestergaard P.; Vojtehovsky M.; Zvolsky P.

Neuroendocrine challenge with citalopram in healthy volunteers
pp. 177-178(2)
Authors: Barnas C.; Schindl M.; Kapitany T.; Schindler S.D.; Heszelmann B.; Sieghart W.; Kasper S.

Melatonin add-on in manic patients with treatment resistant insomnia
pp. 178-178(1)
Author: Bersani G.

Personality as a confounding variable in the study of depressive disorders: A methodological issue
pp. 178-178(1)
Authors: Cavaglia F.; Matos-Pires A.; Arriaga F.

Depression in breast cancer patients - Comparison of paroxetine and amitriptyline
pp. 178-179(2)
Author: Contu A.

Fluoxetine vs maprotiline in the treatment of major depression in hospitalised patients: Comparison of efficacy and side effects
pp. 179-179(1)
Authors: Dossenbach M.; Riedl V.; De Verga V.; Milovanovic D.; Till E.; Klech H.

Double-blind, multicenter comparative study of sertraline versus amitriptyline in outpatients with major depression
pp. 179-180(2)
Authors: Moeller H.-J.; Goebel C.; Glaser K.

Humoral phototransduction.: Is albumine involved?
pp. 180-180(1)
Authors: Grass F.; Oren D.; Huber W.; Kasper S.

Double-blind, multicenter comparative study of sertraline and amitriptyline in hospitalized patients with major depression
pp. 180-180(1)
Authors: Hegerl U.; Gallinat J.; Moeller H.-J.; Arato M.; Janka Z.

Obsessive-compulsive disorder with comorbid major depression: A comparison of sertraline and desipramine treatment
pp. 180-181(2)
Authors: Hoehn-Saric R.; Harrison W.; Clary C.

Citalopram for the treatment of major depression in the elderly: An open naturalistic study
pp. 181-181(1)
Authors: Hranov L.G.; Assenov V.

Severe atypical symptomatology without depression in SAD: Effects of bright light therapy
pp. 181-181(1)
Authors: Ibatoullina E.; Praschak-Rieder N.; Kasper S.

medical treatment in resistant depressive syndrome - Our experiences
pp. 181-181(1)
Authors: Jakovcevska-Kujundziska M.; Filovska V.; Lazarova V.

Pharmacotherapy of depression in elderly patients: The role of sertraline
pp. 181-182(2)
Authors: Jiresch M.; Meszaros K.

The safety of fluoxetine during pregnancy
pp. 182-182(1)
Author: Judge R.

Neuroendocrine responses to the citalopram challenge test in major depression
pp. 182-182(1)
Authors: Kapitany T.; Schindl M.; Schindler S.D.; Heszelmann B.; Barnas C.; Sieghart W.; Kasper S.

Paroxetine: A review of clinical experience
pp. 182-183(2)
Author: Kumar R.

Efficacy and tolerability of paroxetine in the long-term management of panic
pp. 183-183(1)
Authors: Paroxetine Study Group; Kumar R.

Use of the mini-international neuropsychiatric interview to diagnose comorbid depression and anxiety
pp. 183-183(1)
Author: Lecrubier Y.

Combined treatment with mirtazapine and maprotiline in refractory severe depression
pp. 183-184(2)
Authors: Lennkh C.; Fischer P.; Kasper S.

Acupuncture possibilities in depressive patients treatment
pp. 184-184(1)
Author: Gorobetz L.

Steroid-independent translocation of the glucocorticoid receptor by the antidepressant, desipramine
pp. 184-184(1)
Authors: Pariante C.M.; Pearce B.D.; Pisell T.L.; Owens M.J.; Miller A.H.

Influence of a tryptophan-rich diet on brain indoleamines metabolism in the clomipramine animal depression model
pp. 184-185(2)
Authors: Montes J.M.; Mena M.A.; Gaztelu J.M.; Bazan E.; Carazo A.; Saiz-Ruiz J.

Orthostatic hypotension in hypertensive and normotensive elderly depressed women with nortriptyline
pp. 185-185(1)
Authors: Scalco M.Z.; Almeida O.P.; Wanjgarten M.; Serro-Azul J.

Is dizziness a reliable indicator of orthostatic hypotension in elderly depressed women?
pp. 185-185(1)
Authors: Scalco M.Z.; Almeida O.P.; Wanjgarten M.; Serro-Azul J.

The interdependency between stage of depression and blood levels of cortisol, serotonin, prostaglandin E2 and unsaturated fatty acids
pp. 185-186(2)
Authors: Irmisch G.; Schlafke D.; Bollow K.; Engel U.; Ernst K.; Gierow W.; Polak T.; Rehn C.; Richter G.; Richter J.

Amitriptyline versus clomipramine in treatment of male patients with trichotilomania
pp. 186-186(1)
Authors: Ser F.; Veljkovic M.; Marjanovic D.; Lazovic M.; Milovanovic S.

Treatment of atypical depression with sertraline: A double-blind comparative trial with moclobemide
pp. 186-186(1)
Authors: Sogaard J.A.; Verbruggen W.P.; Goodwin D.P.

Mirtazapine in recurrent brief depression (RBD)
pp. 186-187(2)
Authors: Stamenkovic M.; Pezawas L.; Aschauer H.N.; de Zwaan M.; Kasper S.

Efficacy of paroxetine in the treatment of patient disability in social phobia
pp. 187-187(1)
Authors: Stein M.; Pitts C.D.; Oakes R.; Gergel I.

A randomized trial of the effectiveness of sertraline vs interpersonal therapy (IPT) alone or in combination, for people with dysthymia
pp. 187-187(1)
Authors: Browne G.; Steiner M.; Roberts J.; Gafni A.; Byrne C.; Bell B.; Webb M.; Jamieson E.

Management of suicidality in old age depression by family physicians in Germany
pp. 187-188(2)
Authors: Stoppe G.; Sandholzer H.; Aksari P.; Muder C.; Duwe H.; Staedt J.

Diagnosis of depression in the elderly by family physicians in Germany
pp. 188-188(1)
Authors: Stoppe G.; Sandholzer H.; Aksari P.; Muder C.; Duwe H.; Staedt J.

Citalopram in the treatment of depression in patients suffering from simultaneous serious somatic disorders
pp. 188-188(1)
Authors: Tondlova H.; Bastecky J.

Nitric oxide and depression: Voltametric detection of blood nitric oxide on depressed patients
pp. 188-189(2)
Authors: Vandel P.; Burlet S.; Cespuglio R.; Dalery J.

Do drug free depressed sad-patients show higher thalamic/Hypothalamic serotonin transporter density?
pp. 189-189(1)
Authors: Willeit M.; Praschak-Rieder N.; Pirker W.; Neumeister A.; Asenbaum S.; Heelmann B.; Habeler A.; Brucke T.; Kasper S.

In vivo visualisation of serotonin transporters in the human brain during fluoxetine treatment using -CIT and spect
pp. 189-189(1)
Authors: Pirker W.; Tauscher J.; de Zwaan M.; Strnad A.; Bencsits G.; Brucke T.; Kasper S.

Magnesium in mild depressive disorders
pp. 189-189(1)
Author: Bengesser G.

Social aspects of mild antidepressants therapy of youth depressions accompanied by drug use
pp. 189-190(2)
Author: Tzarouk T.

In vivo studies on the brain serotonin output in experimental chronic hepatic encephalopathy
pp. 190-190(1)
Authors: Bergqvist P.B.F.; Hjorth S.; Wikell C.; Apelqvist G.; Bengtsson F.

Multidimensional assessment of suicidal patients. The relationship between biochemical, psychological and psychopathological factors
pp. 190-190(1)
Authors: Ahrens B.; Schumann C.; Berzewski H.; Berghofer A.; Franke L.; Muller-Oerlinghausen B.; Uebelhack R.

A simple method for routine tdm of the novel antidepressant nefazodone and its main metabolite mCPP in serum by HPLC
pp. 190-191(2)
Authors: Bjork H.; Bengtsson F.

Kinetic postmarketing surveillance of the atypic antidepressants mianserine and moclobemide by using routine therapeutic drug monitoring (TDM) databases
pp. 191-191(1)
Authors: Bengtsson F.; Hoglund P.; Liden A.; Nordin C.; Walinder J.

Therapeutic drug monitoring (TDM) of the SSRIs citalopram, paroxetine and sertraline when treating depression in the elderly reduces drug costs
pp. 191-192(2)
Authors: Bengtsson F.; Lundmark J.; Nordin C.; Reis M.; Walinder J.

Postmarketing surveillance by a therapeutic drug monitoring (TDM) routine for SSRIs clearly improves dosing and drug safety
pp. 192-192(1)
Authors: Bengtsson F.; Hoglund P.; Lundmark J.; Nordin C.; Walinder J.

A simple method for routine TDM of the SSRI fluoxetine and norfluoxetine in serum by HPLC
pp. 192-192(1)
Authors: Bjork H.; Bengtsson F.

Which impact has comorbidity in therapy resistant depression?
pp. 192-192(1)
Authors: Bailer U.; Lenz G.

Effect of serotonin uptake inhibitors in panic disorder: A comparison of fluoxetine and citalopram
pp. 193-193(1)
Authors: Amore M.; Magnani K.

Mirtazapine vs amitriptyline and placebo in the treatment of severely depressed patients
pp. 193-193(1)
Author: Kasper S.

Absence of pharmacokinetic (PK) or pharmacodynamic (PD) interactions between zolpidem and fluoxetine
pp. 193-193(1)
Authors: Roth-Schechter B.; Allard S.; MacIntyre J.M.

Pharmacokinetic (PK) and pharmacodynamic (PD) interactions between zolpidem and sertraline in healthy women
pp. 194-194(1)
Authors: Allard S.; MacIntyre J.; Roth-Schechter B.

Drug treatment of depression in the elderly by family physicians in Germany
pp. 194-194(1)
Authors: Stoppe G.; Sandholzer H.; Aksari P.; Muder C.; Duwe H.; Staedt J.

Thyroidal hormone profile in bipolar patients who were in short and long-term lithium treatment
pp. 194-194(1)
Authors: Sofuoglu S.; Tutus A.; Gonul A.S.; Basturk M.; Kose K.; Esel E.

Long term treatment of psychotic pictures and personality disorders with risperidone associated with psychotherapic-rehabilitative approaches
pp. 195-195(1)
Authors: Aduini A.; Critelli E.; Rossetti R.; Mauri M.C.; Laini V.; Invernizzi G.

Drug abuse in schizophrenia
pp. 195-195(1)
Authors: Arias F.; Padin J.J.; Fernandez M.A.; Luengo M.; Hernandez M.S.

Treatment factors associated with schizophrenic relapse
pp. 195-195(1)
Authors: Saenz M.; Paya B.; del Rio J.M.; Gutierrez J.L.A.

Routine therapeutic drug monitoring (TDM) of the neuroleptic compounds risperidon and 9-OH risperidon applied in a pharmacokinetic postmarketing surveillance strategy
pp. 195-196(2)
Authors: Bengtsson F.; Hoglund P.; Bjork H.; Reis M.; Lundmark J.; Eriksson B.; Lindstrom E.; Nordin C.; Walinder J.

Long-acting neuroleptics in preventing relapse and rehospitalization among schizophrenic patients
pp. 196-196(1)
Authors: Boatas F.; Pellejero A.; Aguero C.; Rego A.

Neuroleptic response in chronic schizophrenia and movement disorders
pp. 196-196(1)
Authors: Borner I.; Braunig P.

Hemispheric activation in female patients with schizophrenia and depression during acute episode and after farmacological treatment
pp. 196-196(1)
Authors: Borkowska A.; Rybakowski J.K.

A randomised controlled double blind study of zuclopenthixol acetate compared to haloperidol in acute psychosis
pp. 197-197(1)
Authors: Brook S.; Berk M.; Selemani S.; Kolloori J.; Nzo I.

A prospective randomised double blind controlled study of the efficacy of Lorazepam versus Clothiapine in the control of acutely behaviourally disturbed patients
pp. 197-197(1)
Authors: Subramaney U.; Brook S.; Berk M.

The effect of zotepine on plasma prolactin concentration in the rat
pp. 197-197(1)
Authors: Browning J.G.; Redfern R.J.; Needham P.L.; Heal D.J.

Efficacy and safety of sulpiride in treatment-resistant psychosis
pp. 197-198(2)
Authors: Cetin M.; Ozcubukcuoglu A.; Basoglu C.

A long-term treatment with ''seroquel'' (quetiapine) in a severe schizophrenia patient
pp. 198-198(1)
Authors: Chinchilla A.; Vega M.; Cebollada A.; Ruiz R.

Different profiles of response to noradrenergic and serotoninergic agents in schizophrenic patients resistant to typical neuroleptics
pp. 198-198(1)
Authors: Conte G.; Calzeroni A.; Ferrari R.; Guarneri L.

Response to clonidine augmentation predicts the response to risperidone in schizophrenic patients resistant to typical neuroleptics
pp. 198-199(2)
Authors: Conte G.; Ferrari R.; Calzeroni A.; Scarone S.

Olanzapine versus haloperidol: Analysis of schizophrenic patients from the multi-center international trial
pp. 199-199(1)
Authors: Crawford A.M.K.; Gomez J.C.; Beasley C.M.; Tollefson G.D.

The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentration
pp. 199-199(1)
Authors: Crawford A.M.K.; Beasley C.M.; Tollefson G.D.

What is the differential risk of tardive dyskinesia with the atypical antipsychotic olanzapine?
pp. 199-200(2)
Authors: Dellva M.A.; Tamura R.N.; Glazer W.M.; Morgenstern H.; Beasley C.M.

Do adverse effects of antipsychotics reduce the quality of life of outpatients with schizophrenia?
pp. 200-200(1)
Authors: Dernovsek M.Z.; Tavcar R.

Efficacy and tolerability of risperidone in drug-naive schizophrenic and schizoaffective patients
pp. 200-200(1)
Authors: Diaourta-Tsitouridou M.; Christodoulakis T.; Tsitouridis S.

Functional neuroimaging (ECD-Spect) in schizophrenia - Changement in brain metabolism by atypical neuroleptics
pp. 200-201(2)
Authors: Dirksen-Kauerz U.; Hansen K.; Pietz K.; Czech N.; Bahre M.; Arolt V.

Recognition and management of motor and mental aspects of extrapyramidal neuroleptic syndromes
pp. 201-201(1)
Author: Dose M.

Effect of food on the pharmacokinetics of zotepine and norzotepine in healthy subjects
pp. 201-201(1)
Authors: Faulkner R.D.; Hinson J.; Leone M.B.; Moult J.; Ghani S.; Velagapudi R.B.

A multi-center, one year, haloperidol controlled trial assessing the long term safety, efficacy and quality of life of sertindole in stable schizophrenic patients
pp. 201-202(2)
Authors: Foley S.; Wozniak P.; Silber C.; Mack R.

Clozapine efficacy on suicidal behavior across two main psychiatric disorders
pp. 202-202(1)
Authors: Botsis A.J.; Giotakos O.; Lazaridis P.; Petrovas G.; Stefanis C.N.

''Atypical'' antipsychotics: Antipsychotic activity, extrapyramidal side effects and striatal D₂-like dopamine receptor occupancy as revealed by PET and SPECT
pp. 202-202(1)
Authors: Grunder G.; Yokoi F.; Wetzel H.; Benkert O.; Wong D.F.

Suicide attempts in schizophrenia
pp. 202-202(1)
Authors: Gupta S.; Black D.W.; Arndt S.; Hubbard W.; Andreasen N.C.

Medical resource use and socioeconomics in the treatment of schizophrenia: Olanzapine compared with haloperidol
pp. 203-203(1)
Authors: Hamilton S.H.; Genduso L.A.; Haley J.C.; Revicki D.A.

Sleep deprivation in schizophrenic patients with negative symptoms
pp. 203-203(1)
Authors: Haug H.-J.; Gschwind M.; Naber G.; Hobi V.

Coadministration of clozapine and fluvoxamine in psychotic patients - Clinical experiences
pp. 203-203(1)
Authors: Lammers C.-H.; Deuschle M.; Weigmann H.; Hartter S.; Hiemke C.; Heese C.; Heuser I.

Non-response and missing drug serum levels in longterm treatment with CIS-flupenthixol decanoate
pp. 203-204(2)
Authors: Hoffler J.; Kruger S.; Wittgens W.

Selection bias in clinical trials with antipsychotics
pp. 204-204(1)
Authors: Hofer A.; Walch T.; Hummer M.; Kurz M.; Fleischhacker W.W.

Clozapine in the treatment of first- and multiepisode schizophrenic patients
pp. 204-204(1)
Authors: Hummer M.; Kurz M.; Kemmler G.; Kurzthaler I.; Oberbauer H.; Fleischhacker W.W.

Paroxetine augmentation of neuroleptic treatment in chronic schizophrenia: An open label pilot study
pp. 204-204(1)
Authors: Jockers-Scherubl M.C.; Godemann F.; Pietzcker A.

Tremor in schizophrenic patients treated with antipsychotics
pp. 204-205(2)
Authors: Jogems-Kosterman B.J.M.; Zitman F.G.; van Hoof J.J.M.; Loonen A.J.M.; de Jong W.P.; Hulstijn W.

The efficacy of zotepine in reducing BPRS total score
pp. 205-205(1)
Authors: Kilpatrick A.T.; Welch C.P.; Butler A.; Tweed J.

Neuroleptic malignant syndrome symptomatology in psychiatric inpatients
pp. 205-205(1)
Authors: Havaki-Kontaxaki B.J.; Kontaxakis V.P.; Christodoulou G.N.

Molsidomine antagonised catalepsy induced by nitric oxide synthase inhibitor NNLA and haloperidol
pp. 205-206(2)
Authors: Krzascik P.; Kostowski W.

Changes in psychopharmacological treatment strategies in schizophrenia - Inpatient treatment 1989 vs. 1995
pp. 206-206(1)
Authors: Kurz M.; Hausmann A.; Honeder M.; Kemmler J.; Kurzthaler I.; Walch T.; Wechdorn H.; Fleischhacker W.W.

Pharmacoepidemiology of antipsychotic
pp. 206-206(1)
Authors: Lachaux B.; Gaussares G.; Dhont P.

National survey on patients with antipsychotic
pp. 206-206(1)
Authors: Lachaux B.; Surugue J.; Biscay M.L.

Risperidone in the treatment of acute schizophrenic episodes
pp. 206-206(1)
Authors: Pappas D.; Konitsiotis S.; Liakos A.

The long term cardiovascular safety of sertindole
pp. 207-207(1)
Authors: Mack R.; Driscoll R.; Silber C.

The action of sertindole on negative symptoms in schizophrenia
pp. 207-207(1)
Authors: Mack R.; Foley S.; Silber C.

Clozapine, norclozapine plasma levels during a long term treatment of schizophrenic patients
pp. 207-207(1)
Authors: Mauri M.C.; Bravin S.; Ricci; Boscati L.; Giuliani E.; Guerrini A.; Orlandi R.; Invernizzi G.

Involvement of adenosine A_2A receptors in the induction of c-fos expression by clozapine
pp. 207-208(2)
Authors: Morelli M.; Pinna A.; Cozzolino A.; Wardas J.

Calcium channel blockade changes the effect of haloperidol on alpha₁ adrenergic system responsiveness
pp. 208-208(1)
Authors: Nalepa I.; Kreiner G.; Kowalska M.

5HT2A and DRD4 molecular genotypes in a clinical trial of olanzapine versus risperidone in schizophrenic patients
pp. 208-208(1)
Authors: Nicolini H.; Cruz C.; Camarena B.; Ortega H.

Clozapine and suicide: A case report
pp. 208-209(2)
Authors: Ozpoyraz N.; Tamam L.; Soylu M.L.; Unal M.

A double-blind, placebo-controlled study on gradual withdrawal of antiparkinsonian medication in Chinese schizophrenic patients
pp. 209-209(1)
Authors: Pang A.H.T.; Ungvari G.S.; Chiu H.F.K.; Lam L.C.W.; Chung D.W.S.

Pseudoneurotic form of schizophrenia
pp. 209-209(1)
Author: Piatrowska H.

Weight gain induced by clozapine
pp. 209-209(1)
Authors: Reinstadler K.; Danzl C.; Hummer M.; Kemmler G.; Fleischhacker W.W.

A ten year follow-up of tardive dyskinesia in a nursing home population
pp. 209-210(2)
Author: Rittmannsberger H.

Effects of risperidone and other antipsychotic agents on sleep quality
pp. 210-210(1)
Authors: Royuela A.; Macias J.A.

The use of risperidone for young patients: Clinical experience
pp. 210-210(1)
Authors: Schepens P.; Boriani M.

Acute phase proteins in major depressed and schizophrenic patients during acute episode of the illness
pp. 210-210(1)
Authors: Sluzewska A.; Rybakowski J.K.; Sobieska M.

Effects of clozapine and haloperidol on hematopoiesis
pp. 210-211(2)
Authors: Sperner-Unterweger B.; Kohl C.; Gaggl S.; Miller C.; Herold M.; Hausmann A.; Fleischhacker W.W.

Release of serotonin in brain by neuroleptics: Effect of risperidone
pp. 211-211(1)
Authors: Svensson T.H.; Hertel P.; Nomikos G.G.; Lindblom N.; Arborelius L.

How pharmacotherapy affects factor analysis and internal consistency in schizophrenia
pp. 211-211(1)
Authors: Tacchini G.; Charitos S.; Sironi J.; Penati G.

New perspectives in the treatment of schizophrenic patients
pp. 211-212(2)
Authors: Lesieur P.; Turjanski S.

Interactions of the antepileptic drugs carbamazepine and valproate with the plasma level of haloperidol and the psychopathological outcome of schizophrenic patients
pp. 212-212(1)
Authors: Walden J.; Klose P.; Heszlinger B.; Normann C.; Langosch J.; Berger M.

Case report: Induction of a schizophreniform disorder by a spinal cord stimulator (SCS)
pp. 212-212(1)
Authors: Zdanowicz N.; Janne P.; Reynaert C.; Wunsch A.

Olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
pp. 212-213(2)
Authors: Tran P.V.; Tollefson G.D.; Andersen S.W.; Kuntz A.J.; Hamilton S.H.

The efficacy of zotepine in reducing negative symptoms
pp. 213-213(1)
Authors: Welch C.P.; Kilpatrick A.T.; Butler A.; Tweed J.

Depressive symptomatology during clozapine treatment: Two case reports
pp. 213-213(1)
Authors: Altamura A.C.; Bignotti S.; Tura G.; Curreli R.; Pioli R.

Non-extrapyramidal adverse events in patients treated with risperidone
pp. 214-214(1)
Authors: Amery W.; Zuiderwijk P.; Lemmens P.; Van Baelen B.

Treatment of psychotic disorder in geriatric patients with Alzheimer's desease and functional psychosis - The use of new generation anti-psychotics
pp. 214-214(1)
Author: Apter J.T.

Ziprasidone: Efficacy in the prevention of relapse and in the long-term treatment of negative symptoms of chronic schizophrenia
pp. 214-214(1)
Authors: ziprasidone investigators' study group; Arato M.; O'Connor R.; Meltzer H.; Bradbury J.

The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function
pp. 214-215(2)
Authors: Aweeka F.; Jayesekara D.; Horton M.; Swan S.; Lambrecht L.; Wilner K.D.; Sherwood J.; Anziano R.

¹²³I IBZM spect imaging of dopamine-2 receptors in psychotic patients treated with zotepine
pp. 215-215(1)
Authors: Barnas C.; Tauscher J.; Kufferle B.; Krenn P.; Asenbaum S.; Brucke T.; Kasper S.

Risperidone in elderly patients with psychotic disorders
pp. 215-215(1)
Authors: Madhusoodanan S.; Brecher M.; Brenner R.; Kasckow J.; Kunik M.; Negron A.E.; Pomara N.

The tolerability and efficacy of intramuscular ziprasidone
pp. 215-215(1)
Authors: Brook S.; Swift R.; Harrigan E.P.; Tensfeldt T.

Effect of amisulpride on striatal dopamine and acetylcholine release in the rat
pp. 216-216(1)
Authors: Claustre Y.; Rouquier L.; Allouard N.; Dyon-Laurent C.; Schoemaker H.

Hyperthermia as an occasional therapy
pp. 216-216(1)
Author: Cordeiro Mateus J.M.

Neuroendocrine responsivity to clomipramine challenge test in neuroleptic naive psychotic patients before and after treatment with haloperidol
pp. 216-216(1)
Authors: Daskalopoulou E.; Angelopoulos E.; Markianos M.; Tzemos J.

Genetic study of schizophrenia: Gender and age of onset
pp. 216-216(1)
Authors: Papadimitriou G.N.; Daskalopoulou E.G.; Dikeos D.G.; Stefanis C.N.

Tolerability and cardiovascular safety of risperidone
pp. 217-217(1)
Authors: Lemmens P.; Brecher M.; Baelen B.V.

Clotiapine: Another forgotten treasure in psychiatry?
pp. 217-217(1)
Authors: Lokshin P.; Kotler M.; Belmaker R.H.

Treatment of positive symptoms of schizophrenia: A meta-analysis comparing risperidone with other antipsychotics
pp. 217-217(1)
Authors: Lemmens P.; Van Baelen B.; Brecher M.

Effect of calcium channel blockers on stimulant-Induced hyperactivity
pp. 217-218(2)
Authors: Dogrul A.; Yesilyurt O.; Isimer A.

Extrapyramidal symptoms and sertindole - analysis of three double-blind, Haloperidol-referenced, Phase III clinical trials
pp. 218-218(1)
Authors: Wehnert A.; Stilwell C.; Mack R.; Sloth-Nielsen M.

Delusions of parasitosis - Haloperidol and alprazolam protocol
pp. 218-218(1)
Authors: Ser F.; Marjanovic D.; Lazovic M.; Veljkovic M.

Sertindole in clinical practice
pp. 218-218(1)
Authors: Pezawas L.; Kufferle B.; Barnas C.; Wolf R.; Kasper S.

Effects of oral ziprasidone and risperidone on cognitive functioning in patients with schizophrenia or schizoaffective disorder: Preliminary data
pp. 219-219(1)
Authors: Hagger C.; Mitchell D.; Wise A.L.; Schulz S.C.

Visualisation of dopamine-2 receptor occupancy in psychotic patients treated with olanzapine, risperidone, clozapine and haloperidol
pp. 219-219(1)
Authors: Tauscher J.; Kufferle B.; Barnas C.; Asenbaum S.; Brucke T.; Kasper S.

Typical and atypical antipsychotics differ by their relation to various subtypes of brain dopamine receptor
pp. 219-219(1)
Authors: Rayevsky K.S.; Kudrin V.S.; Ganiev M.M.; Gainetdinov R.R.; Sotnikova T.D.

Clinical and immunological indices of different reaction types on psychopharmacotherapy
pp. 219-220(2)
Authors: Emelyanova I.; Krasnov V.

Clozapine in refractory schizophrenic disorders: A prospective study of efficiency, tolerability and clinical improvement during 18 months
pp. 220-220(1)
Authors: Maitre L.; Poisson N.; Gekiere F.; Dessalles M.C.; Bouchez J.; Villebeseyx V.

An open-label, japanese, Phase II clinical trial of ziprasidone in the treatment of schizophrenia
pp. 220-220(1)
Author: Murasaki M.

The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function
pp. 220-220(1)
Authors: Everson G.; Lasseter K.C.; Anderson K.E.; Egger N.G.; Goeger D.E.; Bauer L.A.; Lill J.; Wilner K.D.; Johnson A.; Anziano R.

Metabolism of zotepine by man and animals
pp. 221-221(1)
Authors: Turton R.W.; McCormick D.J.; Hopper J.B.; Vowles D.T.

Clozapine-induced agranulocytosis: Can olanzapine be a safer alternative?
pp. 221-221(1)
Authors: Shoshani D.; Dorfman P.; Lokshin P.; Ben-Assayag E.; Tran P.; Dossenbach M.

Treatment failure with risperidone: Can olanzapine be an alternative therapy?
pp. 221-221(1)
Authors: Dossenbach M.; Shoshani D.; Sapir M.; Wimmer P.; Belmaker H.

Sleep quality and early morning wakefulness of schizophrenic patients treated with olanzapine compared to fluphenazine
pp. 221-222(2)
Authors: Friedel P.; Dossenbach M.; de Bettignies-Dutz A.

Olanzapine vs. fluphenazine - 6 weeks treatment of acute schizophrenia
pp. 222-222(1)
Authors: Dossenbach M.; Friedel P.; Folnegovic V.; Jakovljevic M.; Hotujac L.; Uglesic B.; Dodig G.

The EPOS project: Increasing our understanding of schizophrenia therapy. Commencement of a prospective, referenced, cohort study of Sertindole in clinical practice
pp. 222-223(2)
Authors: Wehnert A.; Hale A.; Kasper S.; Moller H.-J.; Campbell R.; Stilwell C.; Sloth-Nielsen M.

Creatine kinase levels in first-degree relatives of acute psychotic patients
pp. 223-223(1)
Authors: Hermesh H.; Manor I.; Sechtmann T.; Stein D.; Apter A.; Weizman A.; Munitz H.

Oral versus depot administration of neuroleptics in evolution of 41 schizophrenic patients
pp. 223-223(1)
Authors: Ekonomides D.; Jouvet S.; Dumortier G.; Degrassat K.; Stamatiadis-Mouradian L.

Effects of clozapine and haloperidole on cardiovascular autonomic reactivity in schizophrenic patients: Can autonomic function tests predict the response to neuroleptic treatment?
pp. 223-224(2)
Authors: Agelink M.W.; Kamcili E.; Malessa R.; Zeit T.; Klieser E.

Extrapyrimidal symptom and tolerability profile of 'Seroquel'&unknown; (quetiapine): An overview of phase II/III placebo controlled trials
pp. 224-224(1)
Authors: Atkinson G.A.; Hellewell J.S.E.; Raniwalla J.

'Seroquel' (quetiapine) in the treatment of schizophrenia - Overview of efficacy data in 6 phase II/III clinical trials
pp. 224-224(1)
Authors: Atkinson G.A.; Hellewell J.S.E.; Raniwalla J.

Practical recommendations for the use of Risperidone
pp. 224-224(1)
Authors: Gonzalez de Chavez M.; Sanz M.; Garcia Cabeza I.; Arango C.; Rodriguez Berrueco R.

Subjective response to new antipsychotics
pp. 225-225(1)
Authors: Sanz M.; Cabeza I.G.; Arango C.; Hormaechea J.A.; Gonzalez de Chavez M.

Zotepine, a broad spectrum antipsychotic with low extrapyramidal side effects
pp. 225-225(1)
Authors: Reynolds C.; Kilpatrick A.T.; Bratty R.

Zotepine in the treatment of chronic schizophrenia
pp. 225-225(1)
Authors: Cooper S.J.; Butler A.; Tweed J.; Welch C.P.

A Comparison of zotepine and chlorpromazine on BPRS subscores
pp. 225-226(2)
Authors: Cooper S.J.; Welch C.P.

Clinical questions about clozapine
pp. 226-226(1)
Authors: Siracusano A.; Fiorentini A.

Prediction of acute treatment efficacy in schizophrenic disorder
pp. 226-226(1)
Authors: Ceskova E.; Lorenc M.; Drybcak P.

Creatine kinase levels and familial patterns in acute psychotic patients
pp. 226-226(1)
Authors: Manor I.; Hermesh H.; Sechtmann T.; Stein D.; Munitz H.; Weizman A.

The German postmarketing surveillance of risperidone indaily practice: Gender differences with regard to demographic and treatment data
pp. 227-227(1)
Authors: Albus M.; Linden M.; Klauder A.; Philipp M.

D₂ and 5 HT_2A receptor binding of different doses of quetiapine in schizophrenics, a pet study
pp. 227-227(1)
Authors: Gefvert O.; Wieselgren I.-M.; Hagstrom P.; Bergstrom M.; Lundberg T.; Langstrom B.; Wiesel F.A.; Lindstrom L.H.

Aripiprazole, a new typical antipsychotic: Phase 2 clinical trial result
pp. 227-227(1)
Authors: Petrie J.L.; Saha A.R.; McEvoy J.P.

Depressive symptoms in acute schizophrenia: Evaluation and outcome under new antipsychotics
pp. 227-228(2)
Authors: Muller M.J.; Benkert O.

Saliva levels of clozapine and desmethylclozapine
pp. 228-228(1)
Authors: Dumortier G.; Lochu A.; de Melo P.C.; Zerrouk A.; Nieuwenhuyse V.V.; Rabreau D.R.; Degrassat K.

The clinical actions of risperidone
pp. 228-228(1)
Authors: Marder S.R.; Chouinard G.; Davis J.M.

Paroxetine in panic disorder
pp. 228-228(1)
Authors: Arias F.; Padin J.J.; Fernandez M.A.; Hernandez M.S.; Luengo M.

Sertraline vs clomipramine in obsessive-compulsive disorder
pp. 228-229(2)
Authors: Askin R.; Turan M.; Cilli A.S.; Kaya N.

Salivary cortisol in panic disorder
pp. 229-229(1)
Authors: Bandelow B.; Wedekind D.; Huther G.; Broocks A.; Hajak G.; Sengos G.; Ruther E.

The application of the panic and agoraphobia scale (PAS) in clinical trials
pp. 229-229(1)
Authors: Bandelow B.; Broocks A.; Ruther E.

Panic disorder and agoraphobia: What is effective?
pp. 229-229(1)
Authors: Bandelow B.; Sievert K.; Rothemeyer M.; Hajak G.; Broocks A.; Ruther E.

Panic disorder and agoraphobia: An aetiological model
pp. 229-230(2)
Authors: Bandelow B.; Broocks A.; Hajak G.; Huether G.; Ruther E.

Illness phobia in panic disorder patients: Clinical and course characteristics
pp. 230-230(1)
Authors: Benedetti A.; Perugi G.; Mastalli L.; Simonetti B.; Torti C.; Mata B.; Toni C.

Dizziness, panic attacks and agoraphobia
pp. 230-230(1)
Authors: Allevi L.; Perna G.; Bussi R.; Bertani A.; Bellodi L.

Anxiety disorder and depression -- Epidemiology and pharmakotherapy at comorbidity
pp. 230-230(1)
Author: Boerner R.J.

The 35% CO2 challenge test in patients with generalized anxiety disorder: Preliminary results
pp. 231-231(1)
Authors: Bussi R.; Perna G.; Allevi L.; Caldirola D.; Bellodi L.

Use of sedative hypnotics in elderly psychiatric patients
pp. 231-231(1)
Author: Curran S.

Pindolol augmentation in the treatment of resistant panic disorder: A double-blind placebo-controlled trial
pp. 231-231(1)
Authors: Dannon P.N.; Hirschmann S.; Kindler S.; Iancu T.; Dolberg O.T.; Grunhaus L.J.

Clinical subtypes of panic attacks in panic disorder
pp. 231-232(2)
Authors: Fidaner H.; Tunca Z.; Cimilli C.; Eylul D.

Sumatriptan (5-HT_1D receptor agonist) does not provoke symptoms in obsessive compulsive disorder
pp. 232-232(1)
Authors: Ho Pian K.L.; Westenberg H.G.M.; den Boer J.A.

Alprazolam sustained - Release in the treatment of panic disorder and agoraphobia with panic disorder
pp. 232-232(1)
Authors: Hrdlicka M.; Vachutka J.; Mladkova H.; Rottova J.; Zahradnik P.

Anxiogenic-like properties of urocortin, a novel neuropeptide with preferential activity at CRF₂ receptors
pp. 232-232(1)
Authors: Jenck F.; Kilpatrick G.J.; Moreau J.-L.

The prevalence of social phobia in Hungary
pp. 232-233(2)
Authors: Juranovics J.; Szadoczky E.; Papp Z.; Vitray J.; Furedi J.

Clinico-pharmacokinetic assessment of cassadan in persons with borderline states
pp. 233-233(1)
Authors: Kupriyanova I.; Semke V.; Shushpanova T.; Novozheyeva T.

Effects of D,L-kavain and kava spiss. On extracellular field potentials and long term potentiation in hippocampal slices
pp. 233-233(1)
Authors: Langosch J.M.; Walden J.

The therapy of war-traumatized adolescents
pp. 233-233(1)
Authors: Ljubomirovic N.; Munjiza M.; Popovic-Deusic S.

Efficacy of intensive behavior therapy camp for OCD patients. Part I.: Clinical results
pp. 233-233(1)
Authors: Lukacs E.; Nemeth A.; Morotz K.; Molnar K.; Babel B.

Social phobia: A follow up study
pp. 233-234(2)
Authors: Madaro D.; Socci C.; Nassini S.; Simonini E.; Ruffolo G.; Moretti L.; Perugi G.

Lymphocytes sub-populations in obsessive-compulsive disorder
pp. 234-234(1)
Authors: Marazziti D.; Presta S.; Gemignani A.; Pfanner C.; Placidi G.; Ambrogi F.; Sbrana S.; Rossi A.; Palego L.; Cassano G.B.

The calpain-calpastatin system in obsessive-compulsive disorder
pp. 234-234(1)
Authors: Mundo E.; Soldati L.; Bellodi L.; Bianchi G.

The role of hippocampus in the interaction between GABAergic and 5-HT systems in the expression of anxiety in rats
pp. 234-234(1)
Authors: Nazar M.; Czlonkowska A.; Siemiatkowski M.; Plaznik A.

Epidemiology of OCD in Hungary
pp. 234-234(1)
Authors: Nemeth A.; Szadoczky E.; Treuer T.; Vandlik E.; Papp Z.

Efficacy of intensive behavior therapy camp for OCD patients. Part II.: Tc-99 HMPAO spect study
pp. 235-235(1)
Authors: Nemeth A.; Kopcsanyi Z.; Borbely K.; Lukacs E.; Morotz K.; Molnar K.; Babel B.

Interaction between ondansetron and oxazepam in tolerant rats
pp. 235-235(1)
Authors: Nowakowska E.; Chodera A.; Kus K.

Single photon emission computerized tomogaraphy in obsessive- compulsive disorder (OCD). Different patterns of activation related with illness duration
pp. 235-235(1)
Authors: Facorro B.C.; Encinas M.; Lopez-Ibor M.I.; Cabranes J.A.; Paya B.

Modification of 35% CO2 hyperreactivity with anti-panic drugs and short-treatment outcome in panic disorder patients
pp. 235-235(1)
Authors: Perna G.; Bertani A.; Bussi R.; Allevi L.; Cocchi C.; Gabriele A.; Bellodi L.

GABA_A and GABA_B receptors mediate on locus coeruleus neurons and modulate ECoG and behavioural effects in rat
pp. 236-236(1)
Authors: Rispoli V.; Rotiroti D.

Association study of panic, obsessive-compulsive and eating disorders with a functional polymorphism of the serotonin transporter promoter
pp. 236-236(1)
Authors: Rotondo A.; Mazzanti C.M.; Michelini S.; Gemignani A.; Lezza A.; Capovani B.; Bouanani S.; Coli E.; Miniati M.; Pfanner C.; Presta S.; Milanfranchi A.; Ramacciotti C.; Dell'Osso L.; Mauri M.; Cassano G.B.; Goldman D.

A double blind comparison of lorazepam and oxazepam in psychogenic catatonia
pp. 237-237(1)
Authors: Schmider J.; Standhart H.; Deuschle M.; Drancoli J.; Heuser I.

Fundamental aspects of application of cassadan in therapy of borderline and addictive disorders
pp. 237-237(1)
Author: Semke V.

Predictor of response to a selective serotonin re-uptake (fluoxetine) in the treatment of social phobia
pp. 237-237(1)
Authors: Simonini E.; Nassini S.; Ruffolo G.; Socci S.; Madaro D.; Moretti L.; Gerugi G.

The prediction of nonresponse to pharmacotherapy in panic disorder; a review of the literature
pp. 237-237(1)
Authors: Slaap B.R.; den Boer J.A.

Subtypes of social phobia (aspects of therapeutical response to moclobemide)
pp. 237-238(2)
Authors: Smoulevich A.B.; Kolutskaya E.V.

Peripheral indexes of central serotonergic dysfunction in panic disorder
pp. 238-238(1)
Authors: Stain-Malmgren R.; Sinner B.; Neuger J.; El Khoury A.; &unknown;9berg-Wistedt A.; Wistedt B.

The effect of citalopram treatment on platelet serotonin uptake and ³H-paroxetine- and ³H-LSD-binding in panic disorder
pp. 238-239(2)
Authors: Stain-Malmgren R.; Sinner B.; Neuger J.; El Khoury A.; &unknown;9berg-Wistedt A.; Wistedt B.

Long-term reduction in anticipatory anxiety after multimodal therapy of agoraphobia with panic disorder
pp. 239-239(1)
Authors: Starcevic V.; Bogojevic G.; Kelin K.

Pathological worry and treatment of generalized anxiety disorder with fluoxetine
pp. 239-239(1)
Authors: Starcevic V.; Bogojevic G.

Clinical dynamics of borderline disorders by cassadan therapy
pp. 239-240(2)
Authors: Stepanova L.; Semke V.; Aksyonov M.; Kupriyanova I.

Comparison of flumazenil and lactate in patients with panic disorder
pp. 240-240(1)
Authors: Strohle A.; Kellner M.; Sonntag A.; Holsboer F.; Wiedemann K.

''Pure'' OCD - does it exist? Study of comorbidity in OCD
pp. 240-240(1)
Authors: Vandlik E.; Nemeth A.; Treuer T.; Arato M.

Anterograde amnesia in suicide attempters who took benzodiazepines
pp. 240-240(1)
Authors: Verwey B.; Eling en P.; Zitman F.G.

Panic disorder induced by methylendioxymethamphetamine resolved by paroxetine
pp. 240-240(1)
Authors: Windhaber J.; Maierhofer D.; Dantendorfer K.

Brain serotonergic activity in anxiety induced by repeated social confrontations in mice
pp. 241-241(1)
Authors: Avgustinovich D.F.; Lipina T.V.; Alekseyenko O.V.; Kudryavtseva N.N.

Long-term outcome of panic disorders with and without agoraphobia. Results from a naturalistic follow up study
pp. 241-241(1)
Authors: Carpiniello B.; Altamura A.C.; Baita A.; Sitzia R.; Mannu P.; Macciardi A.

Heart rate variability analysis in post-traumatic stress disorder patients in response to a trauma-related reminder
pp. 241-242(2)
Authors: Cohen H.; Kotler M.; Matar M.A.; Kaplan Z.; Miodownik H.; Cassuto Y.

Double-blind comparison of sertraline and placebo in patients with posttraumatic stress disorder
pp. 242-242(1)
Authors: Davidson J.; van der Kolk B.; Brady K.; Rothbaum B.; Sikes C.; Farfel G.

Panic disorders treatment with psychotherapy and pharmacotherapy combined method
pp. 242-242(1)
Author: Emelyanov U.

Effect of transcranial magnetic stimulation in post traumatic stress disorder: A preliminary study
pp. 242-243(2)
Authors: Grisaru N.; Amir M.; Cohen H.; Kaplan Z.

Fluoxetine in panic disorder: A placebo-controlled study
pp. 243-243(1)
Authors: Lydiard R.B.; Pollack M.H.; Judge R.; Michelson D.; Tamura R.

Recognition and treatment of obsessive compulsive disorder in a pre-paid health plan: Does adequate treatment reduce costs?
pp. 243-243(1)
Authors: Koran L.M.; Leventhal J.; Fireman B.; Jacobsen A.

Buspirone as adjunctive treatment of chronic urticaria
pp. 243-244(2)
Authors: Ser F.; Veljkovic M.; Lazovic M.; Marjanovic D.; Milovanovic S.

Increased prefrontal benzodiazepine receptor density in panic disorder revealed by ¹²³I-iomazenil spet
pp. 244-244(1)
Authors: Stoppe G.; Brandt C.; Meller J.; Keweloh L.; Hoschel K.; Staedt J.; Munz D.

Ultra-long-term pharmacotherapy of social phobia: 4 years treatment with moclobemide
pp. 244-244(1)
Authors: Versiani M.; Nardi A.; Levy S.; Kovacs R.; Amrein R.

Meta-analysis of sertraline in panic disorder
pp. 244-244(1)
Author: Wolkow R.W.

Sertraline 50 mg/day as a treatment for panic disorder
pp. 244-245(2)
Author: Wolkow R.W.

Membrane-protective effect of delta-sleep inducing peptide
pp. 245-245(1)
Authors: Bondarenko T.I.; Goronshinskaya I.A.; Mikhaleva I.I.

Brain acetylcholinesterase activity following administration of 7-methoxytacrine and L-carnitine to rats
pp. 245-245(1)
Authors: Bajgar J.; Herick J.

Comparative studies of different nicotinic agonists in spatial or sequential memory models in aged rats
pp. 245-246(2)
Authors: Bergis O.E.; Moser P.C.; Sanger D.J.

L-dopa alone and with benserazide on the spontaneous activity of striatal neurones in normal and 6-hydroxydopamine-lesioned rats
pp. 246-246(1)
Authors: Chang W.Y.; Webster R.A.

Pharmacological treatment of Alzheimer's disease
pp. 246-246(1)
Author: Curran S.

Donepezil lengthens time to loss of activities of daily living and cognition in patients with mild to moderate Alzheimer's disease
pp. 246-246(1)
Authors: Friedhoff L.T.; Rogers S.L.

Efficacy of cerebrolysin in Alzheimer's disease
pp. 247-247(1)
Authors: Gavrilova S.I.; Selezneva N.D.; Kolykhalov I.V.; Roschina I.F.; Jarikov G.A.

Angiotensin II receptors: New targets for neuroprotection
pp. 247-247(1)
Author: Georgiev V.

Influencing of the central effect of 7-methoxytacrine by brain dominance
pp. 247-248(2)
Authors: Herink J.; Bajgar J.; Kvetina J.

EEG mapping in diagnostic assessment of patients with mild dementia
pp. 248-248(1)
Authors: Kolykhalov I.V.; Iznak A.F.; Chayanov N.V.; Vasilieva A.G.; Zhigulskaya S.E.

The tropicamide pupil test-association with degree of cognitive impairment and interferon-and tumor-necrosis-factor responses
pp. 248-248(1)
Authors: Leszek J.; Inglot A.D.; Kiejna A.; Janczak G.; Wojtowicz B.; Miskiewicz J.

Mild cognitive disorders in elderly GP-patients
pp. 248-248(1)
Author: Mikhailova N.M.

No interaction of apolipoprotein-E and 1-antichymotrypsin polymorphism in Alzheimer's disease
pp. 248-249(2)
Authors: Retz W.; Thome J.; Sitzmann L.; Kornhuber J.; Riederer P.; Rosler M.

Phospholipid and fatty acid composition of different brain regions in patients with Alzheimer's disease and multi-infarct dementia
pp. 249-249(1)
Authors: Ripova D.; Nemcova V.; Hoschl C.; Fales E.; Majer E.; Sikora J.

Interleukine-1 production as a predictor for amiridine therapy efficacy in Alzheimer's disease
pp. 249-249(1)
Authors: Androsova L.V.; Selezneva N.D.; Kolyaskina G.I.; Gavrilova S.I.

Organophosphate-induced delayed polyneuropathy: Possibilities of prevention and treatment
pp. 249-250(2)
Authors: Stepanovic R.M.; Jokanovic M.; Boskovic B.; Maksimovic M.; Ugresic N.

Neuro-immuno-pharmacological profiles of alaptid and selegiline in model experiments with old rats
pp. 250-250(1)
Authors: Tejkalova H.; Benesova O.; Panajotova V.; Kristofikova Z.; Husek P.

Calbindin D-28K and NADPH-diaphorase in the cortex in Alzheimer's disease
pp. 250-250(1)
Authors: Van Gool D.; Tao Z.; Dom R.

Measurement of potential biological markers in Alzheimer's disease - Cerebrospinal fluid levels of amyloid precursor protein and tau protein derivatives
pp. 250-250(1)
Authors: Hock C.; Golombowski S.; Herrmann M.; Nitsch R.M.; Bush A.M.; Muller-Spahn F.

Memory impairment evaluation and Alzheimer's disease treatment: A plurisdisciplinary experience concerning one hundred patients
pp. 251-251(1)
Authors: Bazin N.; Fremont P.; Drunat O.; Vigne C.; Epain V.; Pillet P.

Donepezil improves cognition in patients with mild to moderate AD: Results of ADAS-COG analysis in a 30-week phase III study
pp. 251-251(1)
Authors: Rogers S.L.; Friedhoff L.T.

Donepezil is well tolerated at clinically effective doses for the treatment of Alzheimer's disease (AD)
pp. 251-251(1)
Authors: Rogers S.L.; Friedhoff L.T.

The pharmacokinetics and pharmacodynamics of (R)- and (S)-Warfarin are unaffected by co-administration of donepezil
pp. 251-252(2)
Authors: Tiseo P.J.; Rogers S.L.; Friedhoff L.T.

Co-administration of donepezil and digoxin produces no pharmacokinetic or pharmacodynamic interactions
pp. 252-252(1)
Authors: Tiseo P.J.; Rogers S.L.; Friedhoff L.T.

Risperidone in the treatment of behavioral disturbances in dementia
pp. 252-252(1)
Authors: De Deyn P.; Middleheim A.Z.; De Smedt G.

Ticlid in the treatment of atherosclerotic encephalopathy
pp. 252-252(1)
Author: Dushanova G.A.

Dopaminergic turnover changes on various brain regions during ethanol withdrawal syndrome in rats
pp. 253-253(1)
Authors: Uzbay I.T.; Usanmaz S.E.; Arat S.; Akarsu E.S.

Bipolar disorders treatment with sodium valproate
pp. 253-253(1)
Authors: Alexandrovsky U.A.; Avedisova A.S.

Pilot study of D2 dopamine receptor, ALDH2, ADH2 and ADH3 gene allelic association in polynesian alcohol and cannabis users
pp. 253-253(1)
Authors: Amadeo S.; Noble E.P.; Deparis X.; Brugiroux M.F.; Fourcade-Amadeo M.L.; Tetaria C.; Beaugendre E.; Chaktura F.; Zhang X.; Ritchie T.; Elbaz A.; Cheung E.; Mallet J.

Predictors of outcome in a naltrexone maintenance treatment
pp. 254-254(1)
Authors: Arias F.; Ochoa E.; Lopez Ibor J.J.

Paroxetine vs amitryptiline in depressed alcoholics
pp. 254-254(1)
Author: Cocchi R.

Effects of D₂/D₃ dopamine agonists and antagonists on oral ethanol self-administration in rats
pp. 254-255(2)
Authors: Cohen C.; Sanger D.J.; Perrault G.

Translation validation of the Obsessive Compulsive Drinking Scale in alcoholism:
pp. 255-255(1)
Authors: Schippers G.M.; Deckers F.; Potgieter A.; Lehert P.

Effectiveness of a Methadone Maintenance Treatment (MMT) in Spain
pp. 255-255(1)
Authors: Fernandez-Miranda J.J.; Gonzalez M.P.; Bobes J.

Dependence and negative symptoms
pp. 255-255(1)
Authors: Gobbi G.; Conte G.

Genes coding for dopamine receptors (D2 & D3) and alcohol dependence
pp. 256-256(1)
Authors: Gorwood P.; Ades J.; Batel P.; Sokoloff P.; Schwartz J.C.; Feingold J.

Fluoxetine in severe alcohol dependence
pp. 256-256(1)
Authors: Huertas D.; Bautista S.; Molina J.D.; Chamorro L.

5,7-Dihydroxytryptamine lesion does not affect ethanol-induced discriminative and aversive stimulus effects in the rat
pp. 256-256(1)
Authors: Iwinska K.; Bienkowski P.; Piasecki J.; Kostowski W.

Changes on cerebellar Purkinje cell excitation upon iontophoretic application of cocaine
pp. 256-257(2)
Authors: Jimenez-Rivera C.A.; Segarra O.; Sanabria P.; Waterhouse B.

Peculiarities of drug addiction and alcoholism for the aborigines of the North of Russia
pp. 257-257(1)
Author: Krivogornitsina E.A.

Nimodipine attenuate memory disturbances caused by subanaesthetic dose of ketamine in sober alcoholic patients
pp. 257-257(1)
Authors: Krupitsky E.M.; Ivanov V.B.; Priputina L.S.; Grinenko A.Y.

Early weaning and manipulation of social milieu during pre-puberty affect cocaine reinforcing properties in adult mice
pp. 257-257(1)
Authors: Laviola G.; Dell'Omo G.

Electrophysiological evidence for enhanced processing of drug-related stimuli in opiate users
pp. 257-258(2)
Authors: Lubman D.I.; Chen A.; Deakin J.F.W.

Pharmacotherapy of alcoholic patients
pp. 258-258(1)
Authors: Magyar I.G.; Haszmann A.

Nalmefene modification of alcoholism
pp. 258-258(1)
Authors: Mason B.J.; Salvato F.R.; Cutler R.B.; Williams L.D.

The tridimensional personality questionnaire as a predictor of relapse in detoxified alcohol dependents
pp. 258-259(2)
Authors: On behalf of The European fluvoxamine in alcoholism study group; Meszaros K.; Lenzinger E.; Fureder T.; Hornik K.; Willinger U.; Fischer G.; Schonbeck G.; Aschauer H.N.

The effect of ACPC, a partial agonist of glycine receptors, on rewarding properties of drugs of abuse
pp. 259-259(1)
Authors: Gruca P.; Papp M.

Use of benzodiazepines by drug addicts
pp. 259-259(1)
Author: Rittmannsberger H.

Treatment of depressed alcoholics
pp. 259-259(1)
Author: Roy A.

Pharmacological effects of lisuride shorten, expectations to receive the drug prolong the latency of relapse in weaned alcoholics
pp. 259-260(2)
Authors: Schmidt L.G.; Kuhn S.; Rommelspacher H.

Effects of the calcium channel blocker, nimodipine, on the discriminative and reinforcing stimulus properties of alcohol
pp. 260-260(1)
Authors: De Vry J.; de Beun R.; Manze B.; Lohmann A.; Schreiber R.

Effects of the putative anti-craving compounds naltrexone and acamprosate on operant oral self-administration of ethanol in rats
pp. 260-260(1)
Authors: Schreiber R.; Lohmann A.; Manze B.; De Vry J.

Biopathy and ''quality of life'' in patients ill with chronic alcoholism
pp. 260-261(2)
Authors: Osato J.; Sidorov P.; Soloviov A.G.

P300 abnormality due to chronic alcohol exposure in patients with alcohol dependence
pp. 261-261(1)
Authors: Karaaslan M.F.; Sofuoglu S.; Eren I.; Basturk M.; Gonul A.S.; Reyhancan M.

Markers of thiamine balance in clinical manifestation of alcoholic psychoses
pp. 261-261(1)
Authors: Soloviov A.; Sidorov P.; Bojko E.; Kirpitch I.

Management of dependence of the opioid type
pp. 261-261(1)
Authors: Thuillier M.; Lacour J.; Jullien Y.; Seetharamdoo H.H.S.L.

Neurochemical bases for pharmacological treatment of psychoactive substance dependence
pp. 261-261(1)
Author: Anokhina I.P.

Predictive factors of drop-out in outpatient treatment for drug dependence
pp. 261-262(2)
Author: Castel S.

Comparison of morphine and methadone maintenance in pregnant opiate addicts
pp. 262-262(1)
Authors: Etzersdorfer P.; Fischer G.; Eder H.; Jagsch R.; Schmidl-Mohl K.; Gombas W.; Schindler S.D.

Lithium carbonat in maintaining the abstinence from alcohol
pp. 262-262(1)
Authors: Filovska V.; Jakovcevska-Kujundziska M.; Lazarova V.

Comparison of buprenorphine and methadone in opiate addicts
pp. 262-262(1)
Authors: Fischer G.; Gombas W.; Eder H.; Jagsch R.; Schindler S.D.; Pezawas L.; Kasper S.

Prevalence of hepatitis C in a consecutive investigation of opiate dependent subjects in a drug addiction clinic
pp. 262-263(2)
Authors: Gombas W.; Fischer G.; Eder H.; Okamoto I.; Schmidl-Mohl K.; Schindler S.D.

Alcoholism treatment with antidepressant tianeptine
pp. 263-263(1)
Author: Ivanets N.N.

Reduced blue cone electroretinogram in cocaine withdrawn patients
pp. 263-263(1)
Authors: Roy M.S.; Roy A.; Smelson D.

Buprenorphine maintenance in pregnant opiate addicts
pp. 263-263(1)
Authors: Schmidl-Mohl K.; Fischer G.; Etzersdorfer P.; Eder H.; Jagsch R.; Gombas W.; Kasper S.

Intracerebral haemorrhage associated with ingestion of ''Ecstasy''
pp. 263-263(1)
Authors: Ranalli E.; Bouton R.

Effects of NMDA receptor agonist and antagonist in morphine-dependent rats trained to discriminate naloxone from saline
pp. 263-264(2)
Authors: Bespalov A.Y.; Dravolina O.A.; Medvedev I.O.

Impulsive behaviour with and without alcoholism: Clinical correlates and personality characteristics
pp. 264-264(1)
Authors: Stefos G.; Couturier M.; Monreal J.; Cloos J.M.; Macian F.; Staner L.

MR-imaging in patients with obsessive-compulsive disorder (OCD) with insight as compared to OCD with poor insight
pp. 264-264(1)
Authors: Aigner M.; Zitterl W.; Demal U.; Bach M.; Lenz G.

Erythrocyte inositol monophosphatase activity in obsessive compulsive disorder
pp. 264-265(2)
Authors: Alptekin K.; Kivircik B.; Resmi H.; Ozerdem A.; Tunca Z.

The 35% CO2 challenge test in women with eating disorders: Preliminary results
pp. 265-265(1)
Authors: Arancio C.; Casolari A.; Torres V.; Riboldi S.; Riboldi C.; Perna G.; Bellodi L.

Depression with panic: A 203-case study in private practice
pp. 265-265(1)
Author: Benazzi F.

Repetitive transcranial magnetic stimulation in the treatment of psychotic negative symptoms - A preliminary study
pp. 265-266(2)
Authors: Navarro V.; Bernardo M.; Arrufat F.J.; Buisan E.; Benabarre A.; Masana G.; Font M.

Fluvoxamine controls aggressivity in mentally retarded subjects
pp. 266-266(1)
Authors: Bertelli M.; Cabras P.L.; Conte M.; La Malfa G.P.

Interferon- treatment effect on T-lymphocyte tumor necrosis factor- binding in patients with relapsing-remitting multiple sclerosis
pp. 266-266(1)
Authors: Bongioanni P.; Lupi S.; Mosti S.; Moscato G.; Lombardo F.; Meucci G.

T-lymphocyte interferon- binding in multiple sclerosis patients treated with interferon-
pp. 266-267(2)
Authors: Bongioanni P.; Mosti S.; Lupi S.; Lombardo F.; Moscato G.; Meucci G.

What ''affective temperament'' phenotype for controls in genetic study of manic depressive illness?
pp. 267-267(1)
Authors: Chiaroni P.; Hantouche E.; Azorin J.M.

Association study of bipolar disorder and Msp I/Bal I RLFP at the dopamine D3 receptor gene
pp. 267-267(1)
Authors: Chiaroni P.; Crocq M.A.; Plannels R.; Dassa D.; Henry J.M.; Samuelian J.C.; Azorin J.M.

Influence of cholecystokinin-B (CCK-B) receptor antagonists on rat electroencephalography (EEG): A new class of sleep modulators?
pp. 267-268(2)
Authors: Crespi F.; Trist D.G.; Melotto S.; Reggiani A.; Ratti E.; Gaviraghi G.

Blockade of non-N-methyl-D-aspartate receptors and the anticonvulsive activity of conventional antiepileptics in mice
pp. 268-268(1)
Authors: Czuczwar S.J.; Swiader M.; Kuzniar H.; Kleinrok Z.

Co-occurrence of OCD and HD in an Italian pedigree
pp. 268-268(1)
Authors: Ragone M.A.; Fusco R.; Mennella R.; De Marchi N.

Clozapine treatment of HIV-associated psychosis-too much bone-marrow toxicity?
pp. 268-269(2)
Authors: Dettling M.; Muller-Oerlinghausen B.; Britsch P.

Disorders of sex-role identity at paraphilias
pp. 269-269(1)
Authors: Dvoryanchicov N.V.; Tkachenko A.A.

Quantitative EEG in persons with different forms of paraphilias
pp. 269-269(1)
Authors: Eliseev A.V.; Tkachenko A.A.; Kunikovskiy J.E.

Lithium therapy with concurrent electroconvulsive therapy
pp. 269-270(2)
Authors: Garrido A.; Basurte I.; Basurte E.; Basurte P.; Basurte I.

A SPECT study of obsessive-compulsive disorder
pp. 270-270(1)
Authors: Di Muro A.; Pacciani M.G.; Goracci A.; Luccarelli L.; Castrogiovanni P.; Vella A.; Volterrani D.; Vattimo A.

Cognitive state of hypothyroid patients and thyroid hormone replacement
pp. 270-270(1)
Authors: Bunevicius R.; Gruodis G.

Is there a physiological coupling between melatonin and glucocorticoids?
pp. 270-271(2)
Authors: Hajak G.; Rodenbeck A.; Huether G.; Bandelow B.; Ruther E.

Rebound insomnia after abrupt hypnotic withdrawal
pp. 271-271(1)
Authors: Hajak G.; Clarenbach P.; Fischer W.; Rodenbeck A.; Bandelow B.; Ruther E.

Glutathione levels in a rat model of Parkinson's disease
pp. 271-271(1)
Authors: Tanyalcin T.; Taskiran D.; Kutay F.Z.; Hariri N.I.

Effect of zopiclone on cognition and sleep-EEG in healthy elderly volunteers
pp. 272-272(1)
Authors: Hemmeter U.; Bischof R.; Bruderlin U.; Muller M.; Holsboer-Trachsler E.

Antidepressants versus clozapine in the treatment of depressive syndrome in schizophrenia
pp. 272-272(1)
Authors: Jasovic-Gasic M.; Crnobaric C.; Miljevic C.

Amlodipine enhances the protective activity of ethosuximide and valproate magnesium against pentylenetetrazol-induced seizures in mice
pp. 272-272(1)
Authors: Kaminski R.; Mazurek M.; Jasinski M.; Kleinrok Z.; Cruczwar S.J.

The effect of lithium on histocompatibility antigen type: In vivo
pp. 273-273(1)
Authors: Knag B.-J.; Park S.-W.; Chung T.-H.

Involvement of 5-HT_2A receptors in mediating of the discriminative stimulus properties of DOI in rats
pp. 273-273(1)
Authors: Klodziniska A.; Chojnacka-Wojcik E.

H-MR-Spectroscopy in obsessive compulsive disorder: Evidence for neuronal loss in the cingulate gyrus and the right striatum
pp. 273-273(1)
Authors: Konig A.; Ebert D.; Speck O.; Berger M.; Henning J.; Hohagen F.

The prevalence of allergic diseases in affective and anxiety disorders
pp. 273-274(2)
Authors: Kovacs M.; Arato M.

Use of MAO-A inhibitor moclobemide in fibromyalgia syndrome - First clinical results
pp. 274-274(1)
Authors: Krause K.-H.; Krause J.

Effects of high and low levels of cortisol on pain perception
pp. 274-274(1)
Authors: Lautenbacher S.; Wolf S.; Both-Ortmann B.; Laschefski U.; Vedder H.; Krieg J.-C.

Efficacy and safety of fluoxetine treatment of obesity
pp. 274-274(1)
Author: Krylov V.I.

Effects of cannabis use on cognitive functions and driving ability
pp. 274-274(1)
Authors: Kurzthaler I.; Hummer M.; Miller C.; Sperner-Unterweger B.; Gunther V.; Barnas C.; Wechdorn H.; Battista H.J.; Fleischhacker W.W.

The French Law on biomedical research
pp. 275-275(1)
Authors: Lachaux B.; Aulagner G.; Fondarai J.A.

The treatment of kleptomania with serotonin reuptake inhibitors: A case series
pp. 275-275(1)
Authors: Lepkifker E.; Dannon P.N.; Ziv R.; Iancu I.; Horesh N.; Kotler M.

Temperament as one risk factor of mental disorders
pp. 275-275(1)
Authors: Liivamagi J.; Aluoja A.; Lintsi M.; Peterson J.

DSM IV eating disorders: Diagnostic subtypes targeted pharmacotherapy
pp. 275-275(1)
Authors: Lugo F.; Codazzi L.; Giannelli A.; Zappulli D.; Redaelli G.; Scacchi M.; Cavagnini F.

Auditory evoked potentials in discriminating negative schizophrenia from unipolar depression
pp. 275-276(2)
Authors: Medved V.; Isgum V.

Changes of adenosine deaminase activity induced by stress in rats
pp. 276-276(1)
Authors: Miyahara S.; Komori T.; Shizuya K.; Nomura J.

Psychopharmacotherapy principles of psychoorganic syndrome
pp. 276-276(1)
Authors: Olenicheva E.; Krasnov V.

In vitro and in vivo characterization of CP-154,526, a non-peptide CRF1 receptor antagonist with partial agonist properties
pp. 276-277(2)
Authors: Grosjean-Piot O.; Burgevin M.C.; Achard D.; Pauchet C.; Betschart J.; Imperato A.; Dubroeucq M.C.

Venlafaxine in mental illness
pp. 277-277(1)
Authors: Pieraccini F.; Iapichino S.; Castrogiovanni P.